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The ultimate goal of tissue regeneration is to replace damaged or diseased tissue 
with a cell-based or biomaterial-based tissue that accurately mimics the functionality, 
biology, mechanics, and cellular and extracellular matrix (ECM) composition of the 
native tissue.  Specifically, the ability to control the architecture of tissue engineered 
constructs plays a vital role in all of these issues as scaffold architecture has an affect on 
function, biomechanics, and cellular behavior.  Many tissue engineered scaffolds focus 
on the ability to mimic natural tissue by simulating the ECM due to the fact that in each 
distinct tissue, the ECM serves as a structural component by providing unique 
mechanical strength as well as regions for cellular attachment or the storage of a variety 
of biomolecules.  Additionally, cellular behavior has the ability to be controlled based on 
the structure and composition of the ECM.   More specifically, matrix has the ability to 
modulate a variety of cellular behaviors such as: adhesion, morphology, migration, 
proliferation, and differentiation while also controlling the ability of cells to produce and 
synthesize ECM with similar characteristics to that of surrounding tissue.  Tissue matrix 
and structure plays an essential role during the process of tissue formation, remodeling, 
and regeneration.     
The ability to mimic native tissue ECM using various biofabrication-based 
techniques has become an emerging concept in the realm of tissue regeneration.  
Biofabrication utilizes automated computer-aided-design (CAD) and computer-controlled 
technologies to create reproducible biomaterial and cell-based scaffolds that have the 
ability to imitate native tissue ECM.  Of particular interest are strategies that employ 
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biofabrication with the aim of improving the overall control over scaffold architecture 
and microstructure while also providing reproducibility.    
Due to their versatility, a variety of promising biofabrication strategies exist, 
including rapid prototyping methods such as bioprinting and additive manufacturing, 
which rely on the deposition or extrusion of materials.  Using these methods, a multitude 
of materials can be easily used to fabricate scaffold structures with various morphologies.  
However, the potential of many biofabrication methods in tissue engineering applications 
is limited by the potential resolution of the structures that can be created.  It was our goal 
to investigate a unique biofabrication strategy with the aim of fabricating 3-D scaffolds at 
a high resolution with morphological, biological, and mechanical properties similar to 
those of natural intervertebral discs (IVDs).  
Initially, a CAD-based biofabrication approach was developed and systematically 
optimized. This method was selected to utilize a custom-designed computer interface 
with 3-D motion control that allowed for greater resolution and precision of the 
fabricated scaffold architecture. Furthermore, we incorporated a temperature controlled 
polymer collection stage, which proved advantageous in enhancing the resolution of the 
biofabrication technique.  By lowering the temperature of the collecting stage below the 
freezing point of the polymer solution, it was discovered that the extruded polymer 
solution could be solidified directly as it exited the micropipette extrusion tip through an 
increase in viscosity.  Results from initial studies provided valuable clues towards 
determining the relationship between motor speeds, polymer solution temperatures, 
micropipette size, extrusion rate, and polymer solution viscosity.  These results 
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encouraged the investigation of the ability to use this method to precisely control scaffold 
spatial orientation for the fabrication of IVD scaffolds.   
Since previous IVD scaffold fabrication methods have not effectively accounted 
for the inadequacies of spinal fusion and artificial disc replacement in the treatment of a 
degenerated disc, we addressed the significance of matching native tissue histology and 
biomechanics by using fabricated scaffolds that closely mimic natural IVD tissue.  The 
annulus fibrosus (AF), or outer region of the IVD, was the focus of this project due to 
current and previous challenges in recreating its discrete tissue architecture, which is not 
an issue for the inner nucleus pulposus (NP) region, as it is more commonly mimicked 
with the use of a hydrogel-based biomaterial.   
Multiple elastomeric materials, including biocompatible and biodegradable 
polyurethane (PU) and chitosan-gelatin (CS/GEL), were investigated to evaluate the 
usefulness of this biofabrication approach to create biomimetic IVD scaffolds utilizing 
various materials. It was determined that the biofabrication method enabled the use of 
multiple materials and that the fabricated scaffolds were able to mimic the kidney shaped 
structure of the IVD.  Additionally, the scaffolds exhibited ideal concentric lamellar 
thickness and spacing, accurately mimicking the native structure of the AF in the human 
IVD.  To the best of our knowledge, these accomplishments in recreating the native AF 
histological architecture within tissue engineered constructs have not been achieved 
elsewhere. Cells attached and aligned on the scaffolds in the direction of the concentric 
lamellar structure, emulating cell behavior comparable to the native AF. These 3-D 
scaffolds exhibited ideal elastic properties and did not experience permanent deformation 
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under dynamic loading.  Additionally, the scaffold mechanical properties showed no 
significant differences when compared with native human IVD tissue. The scaffolding 
promoted chondrocyte cell attachment and proliferation in alignment with the concentric 
lamellae, proving this method improves upon current IVD scaffold fabrication 
approaches, as it takes into account native tissue structure and cell response.   
To expand upon these findings, the biomimetic IVD scaffolds were investigated 
to analyze the formation of 3-D cellularized tissue.  3-D multicellular spheroids formed 
from chondrocytes were incorporated within the scaffold to fully cellularize the void 
spacing within the IVD scaffold lamellae.  The ability of this 3-D cellularized structure to 
emulate native IVD tissue was then further analyzed by evaluating the ability of the 
scaffolds to synthesize matrix that was structurally and compositionally similar to that of 
native tissue.  Our studies indicate that the 3-D cellularized IVD constructs accurately 
mimic native IVD tissue and provide not only a scaffold, but a cellularized platform to 
promote tissue regeneration.  Future studies will assess the biofabricted IVD structures 
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1.1 Intervertebral disc (IVD) Degeneration 
Intervertebral disc (IVD) degeneration is characterized by the deterioration of the 
disc tissue.  This deterioration is characterized by unique disorganization of extracellular 
matrix (ECM) within each portion of the IVD.  In the inner region of the disc, the nucleus 
pulposus (NP), proteoglycan (PG) content decreases.  In the outer disc region, the 
annulus fibrosus (AF), the organized lamellar collagenous structure begins to weaken.  
With a decrease in PG content, the inherent water content of the disc reduces.  This 
dehydration within the NP is accompanied by a loss in disc height, and a subsequent 
decrease in swelling pressure.  Further, as the organized AF structure deteriorates, it 
becomes less stable and begins to tear.  This tearing within the AF prevents the annulus 
from containing the swelling pressure from the NP.  The combination of a loss in PG 
content in the NP and a tearing of the collagenous lamellae in the AF, the disc 
degenerates and begins to fail in its duty to support spinal loading.  This degeneration is 
accompanied by a loss in disc height, resulting in compression of the spinal nerves, which 
causes intense back pain for patients, and is oftentimes the underlying cause for patients 
to seek medical intervention. 
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1.2 Clinical Intervention Strategies 
Initially, patients with a degenerated IVD are treated with rest, therapy, and medication.  
Usually, these therapeutic remedies ameliorate the pain and other issues such as resulting 
disabilities. However, when these therapies prove ineffective, surgical intervention is 
necessary.  Discectomy, or removal of the degenerated portion of the IVD, is often the 
first step towards relieving a patients symptoms.  Alternatively, patients can undergo 
spinal fusion to immobilize the degenerated region of the spine, which helps to 
temporarily relieve pain.  However, fusion does not restore disc function or patient 
mobility and prevents natural biomechanical forces on the spine, possibly leading to 
further disc degeneration. 
Recently, patients have also been given the option of replacing the IVD with a 
artificial disc replacement, which have been used in Europe for over a decade and are 
recently gaining interest and clinical approval in the United States.  However, there are 
some downfalls to these current disc replacements.  Though they aid in the preservation 
of motion as well as disc height, they do not replicate physiologic motion or absorb 
compressive forces as their composition is mostly rigid polymeric and metallic materials.  
Due to this composition, these implants may also produce wear particles and cause 
osteolysis.  Furthermore, current implants exhibit significant differences in compliance 
from that of the native tissue, which may cause stress shielding and subsequent implant 
migration into the vertebral bodies. Although these current clinical interventions alleviate 
some symptoms of disc degeneration, they do nothing to address the underlying cause of 
the degenerated disc tissue itself, and often lead to further disc degeneration at adjacent 
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vertebrae levels.  Due to the problems associated with these conventional approaches for 
IVD degeneration, tissue engineered constructs are now being investigated, as they offer 
exceptional opportunities to improve overall patient satisfaction and well being by 
promoting tissue repair. 
1.3 IVD Tissue Regeneration 
Tissue engineering, which is oftentimes referred to as regenerative medicine, is an 
interdisciplinary field that incorporates ideas from: biology, chemistry, materials science, 
engineering, and medicine.  Using a combination of these disciplines, therapeutic 
methods to promote regeneration of many tissues of the body, including the IVD, are 
being investigated by researchers worldwide, including cell-based therapies, signaling 
molecule therapies, and biomaterial-based therapies. These approaches are often used in 
combination, as biomolecule and cell-based therapies alone may prove ineffective in 
supporting spinal loading.  A biomaterial structure is likely necessary to provide 
mechanical stability and support loading throughout the IVD regeneration process, as 
well as provide guidance for cell growth and new ECM organization.  For these reasons, 
biomaterial scaffolds should have similar overall structures and mechanics to that of the 
native tissue.  Additionally, scaffolding constructs provide the ability to incorporate and 
deliver signaling molecules which often enhance the success of the regenerated construct.   
A major goal of tissue engineered constructs is to mimic the targeted tissue’s 
ECM structure and composition with a biomaterial scaffold.  Through mimicry of ECM, 
a biomaterial scaffold provides a platform for the guidance of cellular orientation.  As 
scaffolds with a defined structure can control cell morphology, they subsequently control 
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ECM deposition, including both the type and organization of the synthesized matrix.  
Further, desirable mechanical properties similar to that of native tissue can be achieved 
by controlling ECM composition and orientation on a tissue scaffold. 
1.4 Limitations  
Tissue engineering serves as a promising alternative to the current treatment 
options available for patients requiring surgical intervention due to a degenerated spinal 
disc.  Tissue engineered IVDs may offer the advantage of motion preservation and disc 
space restoration.  However, to date, researchers have not created an IVD tissue scaffold 
that accurately mimics the native tissue histology in combination with similar 
biomechanics of the natural IVD tissue.  In order to engineer a normal IVD structure, the 
materials and structures to be used for IVD tissue regeneration must mimic the 3-D 
histological architecture of the native IVD, which will promote the formation of 
organized cellular and extracellular structures similar to that of native IVD tissues. The 
close correlation between the biological functions and the molecular compositions of the 
disc structures strongly suggests that a major task of IVD regeneration is to create 
scaffolds that precisely reproduce the structural, biological, and mechanical functions of 
the disc structure and organize them in a spatial manner similar to that of the native disc. 
Many researchers have attempted to recreate the IVD, but the discrete tissue architectures 
of the NP and AF have posed great challenges. Furthermore, the biological functions, 
microstructures, and mechanical properties of current scaffolds are far from satisfactory, 
perhaps due to the poor ability to control scaffold architecture during fabrication.  
Although current approaches focused on IVD tissue regeneration are far from 
 5
satisfactory, the results from these studies help to provide a platform towards the creation 
of a successful and clinically-relevant approach to regenerate IVD tissue.  Based on the 
previous successes and failures in tissue engineering IVD scaffolds, we have developed a 
unique strategy attempting to further advance IVD tissue engineering. 
1.5 Project Objective, Significance, and Innovation 
The objectives of this research were to use bioengineering strategies to pursue the 
development of materials and methods to imitate the IVD and facilitate tissue 
regeneration.  To this end, our aims were to use a biofabrication technology to create 
reproducible scaffolds that mimicked the lamellar microstructure of the AF in native IVD 
tissues.  We believe that this biomimetic approach will promote the formation and 
synthesis of ECM more similar in composition, organization, and mechanics to that of 
native tissue, therefore providing a more feasible approach towards regenerating IVD 
tissue.   
The degenerated spinal disc is one of the most expensive medical issues currently 
encountered, as it results in the disability of many people within the aging population.  
This project has the potential to significantly impact worldwide healthcare goals 
involving the restoration of native IVD tissue by decreasing its economic burden and 
impact on society.  The ultimate goal in tissue engineering an IVD is to replace the 
degenerated disc tissue with a functional scaffold that will promote the growth of new 
tissue while also maintaining natural motion and load bearing abilities.  More 
specifically, the strategies described in this work may aid in the promotion of native 
tissue formation to ultimately treat the problems associated with IVD degeneration rather 
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than conventional clinical approaches, which focus only on relieving the symptoms.   The 
aims proposed within this project will generate conceptual advances in understanding 
IVD biomaterial and scaffold implant design criteria, leading to increased technical 
knowledge for the development of a new clinically relevant IVD replacement.   
1.6 Specific Aims and Rationale 
Aim 1: To develop a biofabrication approach that would allow for the creation of IVD 
scaffolds with precise control of scaffold structure. 
Rationale: Current methods focused on creating IVD scaffolds are limited in their ability 
to accurately mimic native IVD structure. To this end, we believe that utilizing a 
computer-controlled polymeric extrusion-based biofabrication approach will enable IVD 
scaffolds to be created with distinct architectures.  Our hypothesis is that this type of 
device, along with the incorporation of a temperature-controlled collection mechanism, 
would allow for the increase of the viscosity of the polymer solution in order to solidify 
precise structures directly upon deposition.   
 
Aim 2: To fabricate tissue engineered scaffolds with structural and mechanical properties 
highly similar to native IVD tissue. 
Rationale: We hope to use our biofabrication approach to create IVD scaffolds with the 
precise characteristics of the native IVD tissue.  Specifically, we want to mimic the IVD 
shape, concentric lamellar structure, lamellar spacing, and its biomechanical properties.  
It is our hypothesis that our unique biofabrication approach will facilitate in the 
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fabrication of complex scaffolds with highly similar biomimetic characteristics of the 
native IVD tissue. 
 
Aim 3: Evaluate the tissue regeneration capabilities of the biofabricated IVD tissue 
engineered scaffolds in vitro. 
Rationale: Elastic lamellar-based scaffolds will be assessed for their potential as suitable 
structures for IVD tissue regeneration.  It is our hypothesis that our constructs will exhibit 
desirable characteristics while demonstrating potential as functional IVD scaffolds for 
tissue regeneration. 
 
1.7 Organization of Dissertation 
The following manuscript is arranged into different chapters that showcase 
individual studies relating to the overall aims of the project.  In Chapter 2, a 
comprehensive literature review is presented.  This chapter focuses on the specifics of the 
IVD structure, the causes and results of disc degeneration, current methods available to 
repair a degenerated disc, and lastly, different methods and techniques that have been 
explored for tissue regeneration of the IVD.   Emerging tissue engineered scaffolds and 
techniques for IVD regeneration are discussed in detail.  Overall assessments of these 
current strategies to enhance IVD tissue regeneration are provided, specifically focusing 
on in vitro and in vivo analyses.  Chapter 3 provides the results from the first 
investigation into our unique biofabrication strategy, which was aimed at creating 
biomimetic IVD scaffold structures.  The results of this experiment proved the ability of 
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the biofabrication method to precisely control polymer extrusion at a high resolution 
while also providing the initial platform towards mimicking IVD shape and structure.  
Mechanical properties of the scaffolds were also investigated to ensure elasticity of the 
constructs.  In Chapter 4, the previous findings are further elaborated upon, showing that 
this novel IVD biofabrication method can utilize multiple polymeric biomaterials in the 
creation of IVD scaffolds.  The ability of the scaffolds to mimic lamellar and 
interlamellar spacing as well as the scaffolds’ ability to control cellular morphology 
similarly to native tissue is discussed.  Finally, it was demonstrated that the biomimetic 
scaffolds have similar mechanical properties when compared to native IVD tissue.  In 
Chapter 5, a 3-D cellularized version of the scaffold discussed in previous chapters was 
fabricated.  It was demonstrated that IVD constructs could be cellularized within the 
voids of their lamellar structure using multicellular spheroids.  Additionally, cellular 
morphology, as well as ECM synthesis were analyzed and compared to native IVD 
tissue.  Chapter 6 summarizes overall conclusions drawn from the body of work and 











Over 80% of the adult population experiences low back pain at some point in their 
lives, resulting in $90 billion in annual costs to alleviate and treat this pain 1-4.  The 
degeneration of the intervertebral disc (IVD) is thought to be the primary cause of low 
back pain, causing compression of the spinal nerves and adjacent vertebrae. It is difficult 
to pinpoint the exact cause of degeneration, but it is thought that many confounding 
factors may play a significant role in the degenerative process. 
The IVD is a tough tissue structure sandwiched between the vertebral bodies 
(Figure 2.1). It has three functions including: 1) acting as a ligament to hold the vertebrae 
of the spine together; 2) a shock absorber; and 3) a “pivot point” that allows the spine to 
bend, rotate, and twist. There are three distinct structures in the IVD: the nucleus 
pulposus (NP), the water-rich gelatinous center that primarily bears the pressure; the 
annulus fibrosus (AF), the collagen-rich fibrous structure of ~15-25 concentric sheets of 
collagen (lamellae) that confines the pressurized NP; and the vertebral end-plates (VEP), 
which are cartilaginous plates that are interwoven into the AF at the disc-vertebrae 
interface and supply nutrients to the disc. All three of the IVD structures contain 
chondrocyte-like disc cells. The NP contains large concentrations of negatively charged 
proteoglycans (PGs), which cause the NP to retain water and maintain its swelling 
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pressure 5,6.  PGs help to maintain water content and swelling pressure in the IVD and 
intertwine in a lose network of collagen type II fibers 5,7,8. The AF has a lamellar 
structure composed of collagen type I and II fibers. This lamellar architecture helps 
maintain the tensile properties of the disc while providing structural support for PG 




Figure 2. 1: MRI of IVD showing NP and AF in distinct regions (left). Schematic of 
spinal column (middle). Anatomy of normal disc with histological stain (right) 10-12. 
  
 
Current treatments to help alleviate low back pain due to IVD degeneration 
include rest and medication.  However, when these methods do not suffice, patients must 
undergo procedures for a spinal fusion or an artificial disc replacement.  Spinal fusion 
helps to temporarily relieve pain, but does not restore disc function and prevents natural 
biomechanical forces on the spine. This possibly leads to further degeneration at adjacent 
levels 13. Therefore, fusion is not ideal as it sacrifices natural motion and may exacerbate 
the problem of further degeneration down the road. An alternative to spinal fusion is an 
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artificial disc replacement, which has been used in Europe for over a decade and is 
recently gaining interest and clinical approval in the United States 14,15. Current disc 
replacements aid in the preservation of some natural motion as well as disc height, but 
they do not absorb compressive forces as their composition is mostly rigid metallic 
materials.  Also, these implants produce wear particles and may cause osteolysis 16.  In 
addition, current implants exhibit significant differences in compliance from that of 
native tissue, which may cause stress shielding and subsequent implant migration into the 
vertebral bodies. Because of the problems associated with these conventional approaches, 
tissue engineered constructs may help promote integration of natural tissue while 
preserving natural kinematics, disc height, and the ability to absorb compressive forces.  
Successfully tissue-engineered IVD tissue must have the native IVD histological 
and macro structures. Therefore, in order to engineer normal IVD structure, the materials 
and structures to be used for IVD tissue engineering must mimic the 3-D architecture of 
native IVD to promote the formation of organized cellular and extracellular structures 
similar to that of native IVD tissues. The scaffolds must allow the infiltration of nutrients 
and removal of wastes to maintain cell viability. The close correlation between the 
biological functions and the molecular compositions of the disc structures strongly 
suggests that a major task of IVD regeneration is to create scaffolds that precisely 
reproduce the structural and biological functions of disc structure and organize them in a 
spatial manner similar to that of native disc. Many researchers have attempted to recreate 
the IVD, but the unique composition and structure of the disc has posed great challenges. 
Furthermore, the biological functions, microstructures, and mechanical properties of 
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current scaffolds are far from satisfactory. The ultimate goal in tissue engineering an IVD 
is to replace the degenerated disc tissue with a functional scaffold that will promote the 
growth of new, healthy tissue while also maintaining the motion and load bearing 
abilities and preventing adjacent disc degeneration. 
2.2 IVD Structure 
 
The IVD is a complex joint which permits flexible motion within the spine while 
serving as a shock absorber. The purpose of the disc is to allow 3-D motion, but also to 
prevent excessive motion and maintain mechanical stability. There are 3 main 
components within the IVD: the NP, AF, and VEP. The NP consists of the soft center 
within the spinal disc, while the outer portion of the disc which surrounds the NP is 
referred to as the AF. The VEP is composed of fibrocartilage and surrounds the disc on 
the top and bottom and separates the IVD from the spinal vertebrae. 
IVDs are composed of cartilage, making regeneration difficult because it is an 
avascular tissue.  Due to its avascular nature, nutrient transport and waste removal is a 
much more complicated process relying solely on diffusion across the VEP and within 
the disc matrix 17-19. The IVD is the largest avascular tissue in the human body, with only 
the peripheral portion of the tissue containing a blood supply. Similarly, there is a lack of 
nerves as well. Some nerve extensions innervate the periphery of the spinal disc, but the 
majority of the disc is not innervated. It is thought that compression of the nerves on the 
periphery of the disc is responsible for a patient’s perceived pain as the disc degenerates. 
A large problem in nutrient and solute transport is the calcification of vertebral endplates 
which occurs as the disc degenerates. If nutrients are not provided to disc cells and waste 
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products are also not removed, then these waste products linger in the matrix of the disc 
preventing the maintenance of healthy IVD chondrocytes.  Decreased nutrition 
accompanied with a loss in PG and water content significantly depletes the ability of IVD 
cells to function properly. Subsequently, disc degeneration occurs if nutrition is depleted 
or impeded. Oxygen concentration gradients change across the cross section of the disc, 
decreasing towards the center as the peripheral cells use the oxygen first 20. Opposite the 
oxygen gradient is the lactate gradient, which is greater in the disc center 20.  The low 
oxygen and high lactate concentrations in the NP create an acidic environment where the 
amount of PG may be subsequently decreased 21. Because the IVD is in a nutrient 
deficient environment, only a small amount of cells can survive. By tissue standards, the 
IVD contains a low cell density, with most of the tissue composed predominately of 
ECM molecules. The main function of cells within the IVD is to constantly secrete ECM 
in order to maintain a stable tissue. As matrix is constantly synthesized, it is also being 
degraded which ensures that the ECM remains a structured environment. This ECM 
consists mostly of PGs, highly concentrated and negatively charged molecules that 
increase the water content, as well as a variety of different collagen molecules which 
promote the strength of the AF 5.  The most prevalent types of collagen are collagen types 
I and II, which make up 80% of the collagen composition within the disc. However, 
collagen types III, V, VI, IX, and XI are also present to help organize the disc into its 




2.2.1 Nucleus Pulposus (NP) 
 
The NP is a gelatinous structure consisting of a large amount of PGs or aggrecans 
with sparsely arranged collagen fibrils serving as supporting matrix (Figure 2.2).  PGs, a 
major matrix component, are glycoproteins containing a protein core and at least 1 
glycosaminoglycan (GAG) chain 22.  The PGs are similar to articular cartilage, also 
containing hyaluronan (HA) 23. Because PGs, and more specifically GAGs, are 
hydrophilic, they maintain a large quantity of water in the IVD. The high concentration of 
GAGs increases the osmotic pressure of the NP and allows it to swell and resist large 
compressive loads 24-26.  It is believed that decreasing the amount of GAGs will decrease 
the disc height and cause disc degeneration as the NP becomes more fibrous. Normal, 
healthy discs represent a changing profile of inhomogeneous material across the disc with 
GAG and water content increasing towards the disc center 27. The purpose of the NP is to 
resist compressive forces and evenly redistribute the forces within the spine. While PGs 
make up roughly 50% dry weight of the NP, the NP is also composed of 25% collagen 
22,28,29.  Collagen type II is highly prevalent in the NP as its concentration decreases 
towards the peripheral AF 22.  Each of these molecules aid in the regulation of growth 










Figure 2. 2: Schematic showing different regions of the IVD and their composition and 
structure (top). Fluorescent imaging showing different cell morphology in different 







Though the ECM is the main component of the NP, it also contains around 4x106 
cells/ml 22.  The cells are mostly chondrocytes and are more rounded as compared to cells 
in the AF (Figure 2.2) 30.  NP cells also develop a larger cytoplasm and a more complex 
structure than AF cells 31.  Characteristic markers for chondrogenic expression of NPs 
include collagen types II and IX, aggrecan, and SOX9 32-35.  
2.2.2 Annulus Fibrosus (AF) 
 
The IVD is largely heterogeneous and exemplifies great differences between the 
NP and the AF (Table 2.1). The AF and NP are separated by what is called the transition 
zone 36.  The AF is present to withstand the tension created during NP deformation. The 
AF is composed of more than 2/3 collagen, where PGs make up only a small percentage 
of its composition 22,28,37. The AF can be separated into the inner AF and the outer AF. 
The outer AF contains an oriented lamellar array of densely packed collagen fibers, while 
the inner AF is similar to the outer portions except it is not as dense and the oriented 
lamellae are not as organized 22. Collagen type I is highly prevalent in the outer AF, while 
its concentration decreases towards the NP 22. The AF has a multilayered, oriented 
lamellar structure with concentric layers creating a regular pattern of collagen type I 
fibers (Figure 2.2) 38.  The collagen fibrils are oriented concentrically with each 
subsequent layer oriented 60° to the spinal column. As the outer AF moves inward and 
approaches the NP, the orientation of the concentric lamellae gradually changes from 
angles of 62° to 45° 39.  
The AF contains roughly 9x106 cells/ml. Cells within the AF resemble fibroblasts, 
showing a thin elongated structure oriented parallel to the collagen fibers within the 
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concentric lamellae (Figure 2.2). The NP and inner AF contain only chondrocytes, while 
the outer AF contains mostly fibrochondrocytes 40.  
 
Table 2. 1: Difference in IVD composition and mechanical properties between the 
annulus fibrosus and nucleus pulposus 41-50. 
 
 Outer AF Inner AF NP 
Water (per weight) 65-75% 75-80% 75-90% 
Collagen (per dry weight) 75-90% 40-75% 25% 
Proteoglycans (per dry weight) 10% 20-35% 20-60% 
Other Proteins (per dry weight) 5-15% 5-40% 15-55% 
 AF NP 
Compressive Modulus (MPa) 0.116-2.3 0.003-.031 
Tensile Modulus (MPa) 0.2-136 N/A 
 
 
As the majority of artificial disc replacements are performed on the lumbar spine, 
this review will focus on that region. Although, spinal disc composition does not seem to 
be significantly affected by the discs level within the spine, the size of the IVD increases 
inferiorly down the spine 51.  IVDs in the lumbar spine are the largest with a height of 
around 1 cm and a diameter of 4 cm 52.  For this reason, the lower back is the most 
common area for disc degeneration, since diffusion of nutrients to the cells is much more 
difficult and takes longer to occur. 
 
2.3 Disc Degeneration 
 
As we age, the disc degenerates. The incidence of low back pain increases with 
age, creating a relationship between age related disc degeneration and the frequency of 
low back pain 22,53. What is less understood are the mechanisms causing this degeneration 
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and the process through which the degeneration occurs.  Many researchers believe that 
the degeneration of the spinal disc is a natural aging process.  IVD degeneration involves 
tissue loss or destruction over time, which decreases disc height and ultimately sacrifices 
mechanical function of the vertebral body. However, evidence suggests other factors are 
involved with increasing disc degeneration such as cell nutrition and transport, the 
presence of degradative enzymes, mechanical loading, smoking, and exposure to intense 
vibrations 54-56.  Although many of these factors may contribute to the aging process, they 
cannot be ignored, leading to the term degenerative disc disease (DDD) which 
encompasses all of the degenerative effects of aging.  
Presumably, it is difficult to characterize the morphology of the degenerated disc. 
Many researchers have developed ways to grade disc degeneration, however, these 
methods do not deal with the entire disc and do not completely characterize all the levels 
of degeneration causing some ambiguity 57.  Clinically, disc degeneration and disc height 
are evaluated using magnetic resonance imaging (MRI).  MRI enables each portion of the 
IVD to be investigated and allows changes in the disc to be analyzed 58,59.  MRI is the 
most clinically effective way to analyze disc degeneration by comparing disc water 
content and height, and looking for tears or irregularities within the tissue 60.  When the 
disc loses height due to tears in the AF or the NP bursting, the compressed vertebrae may 
pinch spinal nerves or rub together, causing intense pain. Some pain from the IVD is 
thought to arise from nerve fiber growth into the degenerated disc 61.  
Disc degeneration may be influenced by calcification with calcium phosphate 
crystalline deposits, as the presence of these deposits increase as the disc ages, hindering 
 19
nutrient diffusion 62.  Also, the amount and size of PGs within the NP significantly 
decreases with as the disc degenerates 41,63-65.  Decreases in PG content are correlated 
with dehydration as these molecules are major contributors to the higher water content in 
the IVD 22.  At early stages of disc degeneration, the NP dehydrates and becomes more 
fibrous 66-68.  Desiccation of the NP is followed by tearing within the AF (Figure 2.3). 
These events may result in further disc matrix degradation, loss of hydration, and 





Figure 2. 3: Picture of normal disc (left) and degenerated disc (right) where the 
degenerated disc is more disorganized and has a more fibrous appearance 69. 
 
As disc degeneration progresses, there is a significant loss in PGs, water, and 
collagen type II. Cellular microstructure may also be compromised during disc 
degeneration. An alteration from a differentiated chondrocyte phenotype to a more 
fibrotic phenotype in the NP occurs 70.  IVD shape and size are altered by changes in 
water content which lead to a hindrance in the discs ability to absorb loads. 
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Matrix turnover is common within the healthy IVD. During disc degeneration, 
matrix is both degraded and altered through a variety of biochemical processes. PGs and 
other ECM proteins are degraded by serine proteinases and matrix metalloproteinases 
(MMPs), cytokines (specifically IL-1 & IL-6), nitric oxide (NO), and prostaglandin E2 
(PGE2) 
22,71,72.  MMPs are catabolic enzymes which encourage matrix degradation and 
studies have shown degenerated discs to contain greater levels of MMPs. One goal to 
stop disc degeneration is to create an environment in which the disc is in a more anabolic 
state in order to increase matrix synthesis and decrease matrix degradation. A normal 
healthy disc inhibits MMPs by using tissue inhibitors of MMPs (TIMPs).  TIMP-1 can 
increase the amount of PG and matrix production.  MMPs 1,2,3,7,8 and 13 have all been 
found in the IVD, with the majority of these proven to be more active in the degenerated 
disc 73,74.  MMP-1 (collagenase), MMP-2 (gelatinase), and MMP-3 (stromelysin) have all 
been directly implicated in aggrecan and matrix protein degradation 75. MMPs 1-3 have 
shown to degrade aggrecan, collagen types I and II, and collagen types IV and V, 
respectively 22.  Interleukin 1 (IL-1) and tumor necrosis factor α (TNF-α) may also affect 
the disc metabolism.  IL-1 may increase the rate of matrix degradation through the 
release of MMPs and may also decrease PG production 76-78.  
The collagens’ organized lamellar structure deteriorates, as well, and the degraded 
matrix molecules become granular and evident within the NP 29,79.  Throughout the aging 
process, the presence of collagen remains the same 5.  However, the different collagen 
types and their ratios appear to change 80,81. Collagen crosslinking is also altered during 
degeneration, decreasing the ability of the disc to support mechanical loads 82.  The 
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increase of disorganized collagen type I with the corresponding loss of collagen type II 
and PGs in the disc matrix has been identified as a reason degenerated discs have inferior 
mechanical properties 83.  
Due to matrix degradation by enzymatic and structural changes, the disc and 
matrix undergo mechanical changes as well. It has been observed that degenerated discs 
have less height and are less stiff than normal discs 84.  Structural changes are thought to 
contribute to disc degeneration, in turn altering the ability of the disc to support 
mechanical loading.  During degeneration, the disc becomes less elastic, preventing its 
ability to absorb and dissipate spinal forces 22,85.  As the IVD is loaded, it loses water 
content. Studies have shown that excessive water movement caused by mechanical 
loading decreases the synthesis of ECM 86. Biomechanical changes in the disc likely aid 
in degeneration. IVD degeneration is identified by altered material properties, ECM, and 
morphology 87,88.  The lamellar morphology of the AF is highly disorganized in 
degenerated discs, while overall disc structure is also modified.  A degenerated disc has 
distorted architecture, responding to stresses differently and possibly causing patients 
perceived pain.  
Cartilage does not maintain the inherent ability to regenerate. As the disc 
degenerates and ages, there is a decrease in the number of viable cells 29,79.  This decrease 
along with a decrease in nutrient delivery have been implicated as important factors 
causing disc degeneration 89.  It is not well understood, but a decrease in cell viability 
may be due to apoptosis of the disc cells caused by mechanical loading of the AF. 
However, many cellular factors must be considered when determining causes of disc 
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degeneration.  Degeneration of the IVD causes a significant structural alteration in both 
regions of the disc, leading to a decrease in height, and ultimately resulting in pain. 
During normal daily life, patients with degenerated discs experience excrutiating pain, 
leading to a decline in their quality of life. The progression of disc degeneration leads to 
further instability in adjacent vertebral levels 90. 
 
2.4 Clinical Solutions to Disc Repair 
 
2.4.1 Discectomy/ Fusion 
 
Currently, it has proven difficult for clinicians to manage the low back pain 
implicated by a degenerated IVD. The majority of patients are treated with rest, exercise 
and/or medications 91. When these therapies are ineffective, surgery is required. The two 
most common surgical procedures for patients with degenerated spinal discs are 
discectomy and arthrodesis. Discectomy is a process in which the degenerated portion of 
the IVD is excised or removed. Arthrodesis is a process of fusing two adjacent vertebral 
bodies together and is often referred to as spinal fusion 92. 
Although removal of degenerated or damaged disc tissue is common, it typically 
leads to a loss in height of the IVD correlated with negative biomechanical changes and 
anatomical problems. Some patients benefit from a discectomy as it may offer temporary 
pain relief. However, postoperatively, the disc structure is highly compromised, leading 
to further degeneration and instability 87. After a discectomy, no regeneration of IVD 
tissue takes place, making further disc degeneration likely 93.  
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Due to the disadvantages and limited success of a discectomy, clinicians often 
turn to spinal fusion to aid in patient comfort and further stabilize the spine.  However, 
the rates of clinical success for spinal fusion are also low 94. The main purpose of spinal 
fusion is to prevent motion within the diseased spine segment. In turn, this loss in 
mobility should decrease a patient’s perceived pain 95. Problems with spinal fusion, 
however, include possible degeneration of adjacent segments and failure to completely 
immobilize the degenerated region of the spine 95. Spinal fusion has proven to increase 
stress concentrations on adjacent motion segments within the spine after analysis using 
biomechanical studies and finite element analysis 96,97. Because discectomy and spinal 
fusion result in a loss of function and may promote adjacent disc degeneration, new 




Discectomy and spinal fusion are only short term solutions to recurring low back 
pain or a degenerative IVD. A total IVD replacement, or arthroplasty, has advantages 
over fusion, eliminating pain while increasing patient mobility 60,95. A primary advantage 
of a disc replacement over spinal fusion is the preservation of some spinal motion 99. 
Implants for disc replacements should be biocompatible, durable, and easily implantable. 
Disc replacements remove diseased tissue and reduce pain by restoring disc height. There 
are different types of disc replacements including a NP replacement and total disc 
replacements. 
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NP replacements are less invasive and promote natural forces on the spine 100.  NP 
implants often have high water contents and promote fluid movement during loading to 
enable nutrient delivery and mimic the native tissue environment. The prosthetic disc 
nucleus (PDN) is a NP replacement consisting of a hydrogel core constrained by a 
biodegradable woven fiber mesh to prevent excessive hydrogel swelling (Figure 2.4) 101.  
The PDN has passed FDA guidelines pertaining to cytotoxicity tests and biomechanical 
fatigue tests 102.  PDN is implanted in a dried form and absorbs fluid after implantation. 
Currently, NP replacements must be implanted through incisions in the AF. This surgical 
trauma, however, may compromise the integrity of the operated disc, resulting in an 
inflammatory response that may ultimately promote the degenerative process. The use of 
a NP replacement is not as widespread as the use of total disc replacement. 
A total disc replacement is used when the integrity of the native AF has been 
compromised or indicated as a cause of pain. Total artificial spinal discs also help re-
establish flexibility of the spine. There are a few commercially available artificial spinal 
discs that have been approved by the FDA. The SB Charitè® and ProDisc® are FDA 
approved in the US with another, the Maverick®, undergoing clinical trials (Figure 2.4) 
15,103-105. The SB Charitè® and ProDisc® have both been used for more than a decade in 
studies done mostly in Europe, and both disc replacements have shown a decrease in 
operative time, blood loss, and length of hospitalization as compared with spinal fusion 
106.  Patients implanted with the ProDisc® and the SB Charitè® reported significantly less 
pain than spinal fusion patients, indicating that the recovery time may be shorter 99,107.  
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Other studies have confirmed the findings that artificial replacements have proven to 
increase patient satisfaction compared with spinal fusion 108,109.  
The SB Charitè® consists of 2 cobalt chromium alloy endplates and a biconvex 
polyethylene (PE) spacer allowing for unlimited axial rotation, but only 20° flexion 
100,110. The endplates are coated with titanium and hydroxyapatite to promote 
osteointegration into the adjacent vertebrae. On the other hand, the ProDisc® consists of 
endplates composed of cobalt chrome molybdenum alloy with a fixed ultra-high-
molecular-weight PE (UHMWPE) bearing surface that articulates on the metal 111.  The 
metal implants contain porous coatings or screws to promote bone ingrowth 100.  The 
Maverick® is an all metal disc implant containing a ball and socket that offers high 
fatigue strength 112.  
  
 
Figure 2. 4: Current Food and Drug Administration approved implants: PDN, SB 
Charitè®, ProDisc® (left- right) 102,113,114. 
 
The use and necessesity of total disc replacements is debatable and comparison 
between different available implants is understudied. However, although there are 
improvements to conventional treatments with artificial discs, there are also drawbacks. 
Problems with current prosthetic devices include extrusion, infection, loosening, and 
cytotoxicity 115-117.  Long term survival and integrity of these implants is unknown 
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because the devices are quite new in clinical use. Problems with a metal on metal 
approach are a large compliance mismatch and the creation of toxic wear debris 100. This 
microscopic wear debris can cause foreign body reaction in the body, and possibly 
destruction of the tissue implant interface 100. As the implants are secured in the vertebral 
bodies, the metal endplates may dislocate or migrate out of the bone. Loosening and wear 
of the PE may occur in the SB Charitè® and ProDisc®, while the PE may also experience 
creep, or even fracture 118-120. Because there are problems with current disc replacements, 
and because they may fail, a revision may be required. Typically, revision operations 
require a removal of the artificial disc followed by spinal fusion to immobilize the 
affected tissue. Revision operations for artificial disc replacements are risky and 
dangerous as scar tissue makes it difficult for the surgeon to navigate the large vessels 
near the spine 121. Therefore, longevity studies analyzing the long term effectiveness of 
current implants are necessary. 
Disc replacements allow some motion, but restrict certain movements and do not 
replicate physiologic spinal motion or stability 118. Total disc replacement procedures do 
not provide an effective treatment method for all patients, as the results are not 
consistently reproducible 95. Other problems involving current disc replacement strategies 
include altered loading and compliance mismatch between the metal/polymer based 
implants and the native tissue 122. Often, current disc replacements do not absorb 
compressive forces. During procedures for discectomy, spinal fusion, and disc 
replacement, degeneration at other disc levels may be increased 123. Although implants 
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for disc replacement currently exist, no methodology has proven completely successful in 
improving the ability of native disc tissue to regenerate. 
 
2.5 IVD Regeneration  
 
An apparent need for an alternative to conventional IVD replacement or spinal 
fusion is obvious. Current artificial discs do not promote tissue remodeling. Tissue 
engineering offers an attractive method to design a biomaterial that will aid in the 
regeneration of natural IVD tissue. As current surgical procedures only focus on 
symptoms related to IVD degeneration, IVD tissue engineering offers multiple strategies 
to prevent and possibly cure degenerated discs by encouraging tissue repair. Tissue 
engineering promotes tissue regeneration by encompassing the use of biomaterial 
scaffolds, stem cells, and growth factors. 
Therapeutic strategies for tissue engineering are advantageous because they can 
be implanted simultaneously with a discectomy. Once removed, appropriate biomaterials 
that have been designed to possess the desired biological, chemical, physical and 
mechanical properties can then replace degenerated tissue. These biomaterial structures 
should not illicit an immune response, have a structure similar to native tissue, be 
biocompatible and biodegradable, and exhibit similar mechanical properties to those of 
the natural tissue after successful regeneration. Many biomaterials currently exist which 
have proven their biocompatibility, but newly developed materials must pass this 
requirement first and foremost 124. However, not all materials are suitable for every 
application, and when choosing materials for the IVD many factors should be considered. 
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An ideal scaffold would be porous to provide cell attachment and tissue ingrowth, while 
also allowing the diffusion of nutrients and waste. The porous structure should allow 
room for ECM to be secreted and ultimately form the tissue similar to normal native IVD 
tissue. 
Though biomaterial-free approaches do exist, in the spine, it may be necessary to 
use biomaterials, as they serve as a load bearing structure to support biomechanical forces 
while cells proliferate and create their own matrix. Biomaterials are important to provide 
a stable environment for disc tissue regeneration 125. Because the native disc has a low 
density of cells, there is great concern that without a biomaterial carrier the implanted or 
recruited therapeutic cells will have trouble synthesizing functional matrix to support 
IVD biomechanics. Biomaterial carriers or scaffolds are important because biomaterials 
offer cells a 3-D environment to guide cell behavior. Biomaterials can guide cell 
attachment and growth along a defined micro and macrostructure to better mimic native 
tissue structure. However, for tissue engineering purposes, it is important to note that 
seeding cells at a high density is not attractive due to the unique IVD environment, which 
is not conducive to maintain the viability of a large population of cells 11.  
A biomaterial structure or therapy for disc regeneration should be able to handle 
normal physiologic stresses on the IVD, which have been measured at around 1 MPa 47. 
Biomaterial supporting structures should also be able to handle continuous dynamic 
loading over time while proving fatigue resistant. Also, for tissue engineering, it is 
important for the biomaterial to degrade over time and allow natural cell and ECM based 
tissue to take its place. When designing biodegradable materials, it is important to control 
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the degradation time and alter it in order to allow for new tissue infiltration. It is also 
important to evaluate the degraded material and verify it to be non-toxic to prevent an 
adverse immune response. Many materials offer the advantage of being able to have their 
mechanical properties and degradation times specifically tailored by creating copolymers, 
varying molecular weights, and altering crosslinking density. These materials include 
both synthetic and natural biomaterials, with many of these polymers showing superb 
biocompatible properties. Natural materials offer an advantage of promoting cell 
attachment and cellular recognition of the material. However, it is much easier to tailor 
the mechanical and physical properties of synthetic materials. Each of these material 
types show promise for IVD tissue regeneration.  
One major hurdle in the development of a scaffold for IVD tissue engineering is 
the ability of researchers to mimic the lamellar organization of the AF 11. The native disc 
histology and dynamics should be mimicked in biomaterial structures for IVD 
regeneration. In this regard, the ability of a biomaterial structure to enable natural motion 
may help prevent tissue degeneration at adjacent disc levels while encouraging natural 
tissue regeneration. 
Tissue engineering techniques are mainly evaluated on the ability to increase 
ECM synthesis and restore disc height. When evaluating a biomaterial structure, cells in 
the NP region should be more morphologically rounded as this morphology has proven to 
synthesize more collagen type II, while cells in the AF region should be more elongated, 
as this morphology has proven to synthesize more collagen type I 11.  The majority of 
successes with tissue engineering approaches for IVD regeneration have focused on the 
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production of ECM and PGs which increase water content and mechanical stability. 
Qualitative studies such as staining with H&E, Alcian Blue, and Safranin-O are useful in 
evaluating specific cell behavior and matrix synthesis on scaffolds.  
 
2.5.1 Cell Based Therapy 
 
A large focus in the field of IVD tissue engineering is currently supported by cell 
based transplantation therapies. Mesenchymal stem cells (MSCs) are thought to halt IVD 
degeneration and possibly regenerate some tissue despite the degree of degeneration 126.  
MSCs can be found in bone marrow, adipose tissue and many other connective tissues 
and are a multipotent type of adult stem cell that are less susceptible to tumor formation 
than embryonic stem cells 126,127.  Stem cells can be differentiated down a chondrogenic 
pathway and may have the ability to express IVD cell phenotypes. Because MSCs lack 
HLA class II antigen expression, they may have the ability to be used for allogenic 
transplantations 128.  The delivery method of cell based therapies would be primarily 
through injection into the IVD.  
MSCs in hypoxic situations (2% O2) exhibit a tendency to differentiate towards a 
phenotype similar to that of NP cells 4.  Under hypoxic conditions MSCs increased the 
amount of surface receptors for matrix and integrins, specifically β1, β3, and α2 integrins 
while maintaining desired levels of CD44 (hyaluronan receptor), CD105, CD166 
(ALCAM) 4. When injected into the degenerated disc tissues, stem cells may naturally 
differentiate towards a chondrocyte phenotype based on the environmental cues. MSC 
transplantation has shown to restore native disc height, cellularity, and structure in animal 
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models (Figures 2.5 & 2.6) 123. Transplantation of human chondrocytes has proved 
effective in the therapeutic treatment of lesions within cartilage tissue 129.  However, 
chondrocytes are difficult to obtain for cell culture due to their limited availability in the 










Figure 2. 6: MSCs transplanted (arrow shows injection site) into the NP region at 2 
weeks (a), and at 24 weeks (b) with circled region showing increased cell viability and 
expansion at 24 weeks 123. 
 
Autologous cells would likely be approved clinically as immune rejection would 
not pose a threat. Recent success has been shown in this field as injected autologous cells 
have reduced pain and maintained disc height 130.  Autologous disc chondrocyte 
transplantation (ADCT) is a procedure where patients’ own cells are transplanted into the 
disc region 12 weeks after a discectomy 130. A large scale, multicentered, randomized 
clinical trial called EuroDisc evaluated the effectiveness of ADCT 130. Two years after 
ADCT, patients showed a decrease in pain, with a significant increase in PG and fluid 
content as compared to patients who underwent discectomy alone 130.  The study was 
considered a success as one of the primary goals for IVD tissue engineering is to 
eliminate patient pain. 
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Cell therapy and injection based methods may have limitations because cell 
leakage could occur after injection 131.  Also, injected cells must be able to remain viable 
in vivo under high pressure and also must produce ECM to help increase disc height. This 
may prove very difficult without the use of a biomaterial carrier for initial mechanical 
support 132.  Another disadvantage for biomaterial-free methods is the inability to support 
in vivo biomechanical forces during tissue regeneration 125. Autologous cell based 
approaches are not efficient as they require multiple operations to retrieve the cells and 
then implant the expanded cells back. The use of autologous cells also appears to be an 
expensive and time costly procedure. Using allogenic transplantations may allow stem 
cells to be expanded in vitro to create a steady supply of on demand cells for therapy. 
Stem cell lines may also be readily accessible, but their future use clinically remains in 
doubt due to a lack of understanding and possibility of tumor growth.  
 
2.5.2 Signaling Molecule Based Therapy 
 
Different signaling molecules are also being investigated as therapeutic strategies 
for the treatment of disc degeneration. Molecular therapy offers a way to reduce disc 
degeneration and possibly prevent or reverse the entire process of degeneration. If 
signaling molecules were to be used alone, they would have to be injected into the 
degenerated portion of the disc using a needle. Using multiple molecules to signal more 
than one cell activity may be more effective than using a single signaling molecule 70, as 
each of these molecules may play a specific role in allowing the IVD to regenerate 70. 
Table 2.2 summarizes signaling molecules, and whether they function as mitogens or 
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chondrogenic morphogens. Certain signaling molecules can decrease the inflammatory 
response and therefore protect the disc from further degeneration. Signaling molecule 
therapy to regenerate the IVD may prove to be an especially important therapy in early 
stages of disc degeneration, where disc structure has not yet been compromised. 
 
Table 2. 2: Different categories of therapeutic molecules for the IVD.70 
 
Category Molecule 
Mitogens IGF-1, PDGF, EGF, FGF 
Chondrogenic 
Morphogens 
TGF-β, BMP-2, BMP-7 (OP-1), BMP-13 (GDF-6, CDMP-2), 
GDF-5 (CDMP-1) 
 
Signaling molecules and their expression patterns in the normal IVD are essential 
to understand the differentiation of IVD cells. Signaling molecules bind to specific 
receptors, activating signaling responses to control cell behavior 133. Signaling molecule 
therapy explores the idea that different signaling molecules may work together to allow 
tissue remodeling. In addition to the use of signaling molecules, matrix is continuously 
synthesized and degraded in the IVD, which provides the opportunity to use enzymes and 
inhibitors to increase matrix synthesis or slow degradation.  
Signaling molecule therapy may be a viable strategy for promoting the restoration 
of native disc matrix. Mitogens are molecules that help cells proliferate or increase the 
rate of mitosis. It has been shown that mitogens, such as insulin-like growth factor-1 
(IGF-1), epidermal growth factor (EGF), and fibroblast growth factor (FGF), increase the 
rates of disc cell mitosis 70. It also demonstrated that some mitogens, such as IGF-1 and 
PDGF, also upregulate PG synthesis 134. Further, some mitogens such as PDGF and IGF-
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1 have proven to help preventing the apoptosis of AF cells 135,136. Chondrogenic 
morphogens can differentiate cells to express a chondrocytic phenotype instead of a 
fibrotic phenotype. Transforming growth factor-β (TGF-β), bone morphogenic proteins 
(BMPs), and growth and differentiation factors (GDFs) are molecules characterized as 
chondrogenic morphogens. The synthesis of type II collagen, Sox9, aggrecan, and GAGs 
is associated with chondrogenic morphogens as well 70. Of these molecules, TGF- β1 was 
found to best maintain IVD chondrocyte viability 137. Some chondrogenic morphogens, 
such as TGF- β1, are able to increase disc cell proliferation and PG synthesis 138, and in 
the meantime to decrease the activity of MMP-2, which slows disc degeneration 138,139. 
Some chondrogenic morphogens, such as bone morphogenic protein (BMP-7), also called 
osteogenic protein-1 (OP-1), can increase the synthesis of multiple disc matrix proteins, 
such as PG, aggrecan, and type II collagen 140-142. Figure 2.7 demonstrates that OP-1 
significantly increased the production of PGs 142. Because that, BMP-7 has the 
therapeutic role to aid the regeneration of the NP after injection and increase disc height 
143,144. Interleukin-1 (IL-1) and MMPs have been found in degenerated discs, all of which 
increase matrix degradation 60,71,72,75,145. Therefore, activities of IL-1 and some MMPs 
should be inhibited to stop disc degeneration 146,147. BMP-7 inhibits the inflammatory 




Figure 2. 7: PG content in the NP was significantly greater than the other IVD regions 
when treated with BMP-7. All regions showed significant difference in PG content 
when treated with BMP-7 when compared to controls 142. 
 
Many different signaling molecules have been implicated in IVD regeneration. 
BMP-2 provides evidence of a natural affinity to increase cellular differentiation towards 
a chondrocytic phenotype because it increases the expression of aggrecan, a PG, and type 
II collagen. BMP-13, also called GDF-6 or cartilage-derived morphogenetic protein-2 
(CDMP-2), has also proven to increase PG synthesis, though less effective than BMP-2. 
GDF-5, also called CDMP-1, which has been found in precartilaginous development of 
long bone formation, has worked better than TGF- β1, IGF-1, and FGF in restoring disc 
height in experiments. Similarly, FGF has shown to increase matrix production 
throughout the disc 70,138,149.  Walsh et al. have also analyzed the efficacy of different 
signaling molecules, including GDF-5, IGF-1, FGF, and TGF-β1, for IVD regeneration 
150.  Cell population increased in the NP and inner AF in response to GDF-5 while the NP 
of TGF-β1 treated discs also showed evidence of cell aggregates, suggesting that GDF-5 
and TGF-β1 promote disc regeneration 150. As many signaling molecule based studies 
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have not provided concrete evidence, more thorough examination on the effects of each 
biomolecule is needed. 
Cell and biomolecule based therapies will likely only be successful at the 
beginning stages of disc degeneration, before the disc composition and morphology have 
changed dramatically 126.  Drawbacks to growth factor therapy are that the degenerated 
portion of the disc cannot be removed and the disc height is not increased initially. 
Another major downfall is the biomolecules’ short half-life 151. If signaling biomolecule 
based therapy is to be successful, it should be coupled with a biomaterial carrier in order 
to avoid biomolecule denaturation. These biomolecule should have a temporal release 
profile in order to control the release amount. The ideal biomaterial could release 
desirable biomolecules into the IVD to promote successful tissue regeneration while also 
increasing the disc height and mechanical stability. One example using biomaterial to 
assist biomolecule based strategy is incorporating platelet-rich plasma (PRP) into gelatin 
microspheres, which allows injection of the material into the NP 152. PRP contains many 
signaling molecules that have been implicated to promote IVD tissue regeneration, while 
improving PG synthesis in the IVD (Figure 2.8) 152,153. These gelatin microspheres served 
as a delivery vehicle to enable the sustained release of growth factors from the PRP to 




Figure 2. 8: Optical density of PGs in the NP (A), and AF (B) showing that discs 
treated with PRP loaded gelatin microspheres showed a much higher presence of PGs 




Biomaterials that crosslink and gel upon injection into the desired site may show 
promise in the application of IVD regeneration. Injectable biomaterials are important 
because they are less invasive than most conventional surgical techniques. Hydrogels, 
which are in this class of injectable biomaterials, absorb large quantities of water and will 
facilitate disc regeneration by acting as a temporary scaffold and increasing hydration 
while aiding nutrient transport. They can also serve as a carrier or delivery vehicle for 
cells and signaling molecules. These materials, however, may only aid in the regeneration 
of the NP as the materials are physically and mechanically most similar to this portion of 
the tissue. IVD cells in some hydrogels will take on a natural rounded morphology, 
similar to that in the NP. Replacing the degenerated NP with hydrogels is an attractive 
method for NP regeneration. As recently as 2005, the FDA has proposed the use of more 
non-invasive therapeutic strategies to prevent disc degeneration, such as hydrogel 
injection into the NP 154,155. Most of the hydrogels currently under investigation are 
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liquids at the time of injection, and undergo a gelation process after injection 123. Many 
hydrogel materials may be used for IVD tissue engineering.  
 Different hydrogel materials have been developed to mimic the NP of the natural 
IVD 11. Baer et al. used an alginate hydrogel to preserve the IVD cell phenotype. The 
IVD cells seeded in alginate demonstrated enhanced production of PGs, collagen types I 
& II, keratin sulfate, and chondroitin sulfate, all of which are constituents of the native 
disc 27. However, the alginates anionic traits may prevent the formation of collagen into 
its natural fibrillar structure. Chondrocytes cultured in agarose gel maintained a collagen 
and PG structure comparable to that of natural cartilage 27. 
Collagen hydrogels are attractive as they are constituents of native disc tissue. NP 
replacement with collagen gels has proven to restore disc height with advantageous 
mechanical properties in bovine animal models 156.  Also, collagen type I gels have 
proven to promote IVD cell proliferation while also expressing both anabolic and 
catabolic genes, signifying matrix synthesis and degradation, respectively 125. These 3-D 
gels were used to determine how cyclic strain and hydrostatic pressure affected cell 
behavior 125. Cyclic strain at a physiologic frequency of 1 Hz increased anabolic 
expression of collagen type II and aggrecan while also decreasing catabolic expression of 
MMP-3 125.  Hydrostatic pressure increased expression of collagen I and aggrecan while 
it decreased expression of MMP-2&3 125.  Therefore, moderate mechanical loading may 
aid in matrix synthesis while also decreasing matrix degradation 125. Collagen hydrogel 
has already been used to regenerate cartilage clinically 157. Collagen gel promotes IVD 
cell viability and the production of native matrix to prevent a significant loss in disc 
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height 158. Furthermore, collagen hydrogels loaded with MSCs helped preserve the NP 
and the structure of the AF in animal models, allowing for enhanced disc regeneration as 
compared to collagen alone 123. Some researchers are also investigating type II collagen 
hydrogel for IVD regeneration. Type II collagen is the dominant collagen type in native 
NP tissue and support NP cells very well. However, type II collagen degrades rapidly and 
only last for 2-3 weeks, which is not sufficient time to allow functional matrix to be 
synthesized to support physiologic loading 123,154. Most current studies on collagen gel 
are only focus on the regeneration of one region of IVD tissue 158. A better strategy 
would be using heterogeneous hydrogel for the regeneration of different regions of IVD 
tissues. 
Hyaluronan (HA) gel is another material often used in IVD regeneration because 
it is a natural component of the native disc matrix, as well as because it increases the 
water content within the scaffold to enhance the discs load bearing capacity 93,159,160. 
Injectable HA hydrogels have proven to prevent fibrotic tissue formation after removal of 
the NP in pig animal models 161. In one study, viscous HA hydrogels were used as 
biomaterial carriers for the delivery of MSCs into rat coccygeal discs 91.  Four weeks 
after injection, cell viability increased 91. However, after 4 weeks, the discs treated with 
the MSC therapy did not show a significant difference from the sham operated animals 91. 
This may be because sufficient matrix was not produced. 
Chitosan hydrogel has been proposed to serve as a NP replacement 162. Chitosan 
is especially attractive for IVD regeneration as it has shown to promote chondrocyte 
attachment and proliferation while having similar properties to extracellular matrix 
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(ECM) in native cartilage  163-166. Chitosan has the ability to self associate or form 
covalent cross links, which enables a more complete hydrogel network. This type of 
crosslinked hydrogel allows time for cells to manufacture ECM since polymer 
degradation time is increased. Chitosan hydrogels can enhance the viability of 
chondrocytes and aid in an increase of aggrecan synthesis 52. Cationic chitosan may be an 
ideal biomaterial hydrogel to use as a replacement for the NP portion of the IVD because 
it may aid in the attraction of anionic aggrecan molecules 52. This attraction would allow 
for the possible accumulation of PGs and subsequently an increase tissue hydration. In 
one particular study, lower molecular weight chitosan (2.5% Protasan UP G213) 
exhibited superior cell viability compared to higher molecular weights 162. Using 1% to 
1.5% cationic chitosan hydrogels seeded with NP cells, roughly 80% of the synthesized 
PG content was retained in the hydrogels 52.  
Synthetic hydrogels can be manipulated to provide different mechanical 
properties depending on their application.  Some of the synthetic hydrogels used in IVD 
regeneration include polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyvinyl 
pyrrolidone (PVP), and polyethylene oxide (PEO)-polypropylene oxide (PPO). PEG 
hydrogels have been used as biomaterial carriers to deliver MSCs into the NP in rat 
spines while maintaining cell viability 167. PVA/PVP hydrogels have also been developed 
to serve as minimally invasive, injectable NP replacements 168.  However, no evidence 
was provided proving the ability of a PEG hydrogel to withstand loading or aid in matrix 
retention while the PVA/PVP materials have not been proven to produce cell morphology 
similar to the native NP 167,168.  Pluronic F-127 , a PEO/PPO copolymer hydrogel allowed 
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the synthesis of cartilage tissue, however, it cannot retain its initial shape and is 
unsuitable for mechanical loading.169 Although few synthetic hydrogels are currently 
investigated for NP applications within the IVD, many synthetic biomaterials are being 
developed to mimic the AF structure which will be discussed later. 
Currently, most studies on hydrogels for IVD applications are focusing on natural 
based materials. Although synthetic materials and their properties are easier to control, 
natural hydrogels provide a better environment to mimic the NP of a disc implant. One 
issue with injectable hydrogels is their propensity to leak out of the injection site before 
completely curing/gelling. Because hydrogels are mostly used to mimic the NP, other 
biomaterial structures are investigated to better recreate the overall structure of the AF 
and the native disc as a whole.  
 
2.5.4 Biomaterial Scaffolding 
 
 A variety of solid biomaterial scaffolds have been investigated for IVD tissue 
regeneration. Because fibrochondrocytes may require chemical and mechanical signals in 
order to function and regenerate normal IVD tissue, scaffolding that has the ability to 
support physiologic loading is desirable 170. Given the unique structures of IVD tissue at 
different regions, it is important for scaffolding constructs to accurately address the 
structure and composition characteristics of each region. More specifically, the NP and 
AF structures need to be better mimicked to provide direction and guidance for cell 
alignment and matrix deposition.  
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Annulus Fibrosus Scaffolding 
Many different polymeric biomaterials have been used in attempts to regenerate 
the AF. PLA, PGA, and the copolymer PLGA appear attractive for tissue scaffolds 
because suture products based on these materials have been approved by the FDA for 
human use 171.  However, PLA and PGA alone are problematic for IVD applications 
because they are hydrophobic and do not promote cell adhesion 172. Therefore, they are 
often combined with other materials to enhance cell responses. Examples of these types 
of materials include small intestine submucosa (SIS), demineralized bone matrix (DBM), 
and gelatin, which have been combined with PLGA  to improve cell attachment and 
growth 171,173. Another downside to the use of PLA, PGA or its copolymers is that their 
acidic degradation products elicit an inflammatory response 171. 
SIS is an acellular material containing 80-90% oriented collagen fibers, GAGs, 
and growth factors, including bFGF, VEGF, and TGF-β 174,175. Biodegradable SIS 
scaffolds improve PLGA materials for IVD applications as they allow incorporation of 
growth factors to increase metabolic activity and matrix production of cells 176.  Further, 
positive gene expression proved that acellular SIS materials promoted ECM and GAG 
production (Figure 2.9) while improving cell migration into the material after 1 month 
176,177.  Also, SIS resorbs in 3 months, which is beneficial for IVD tissue regeneration as 
it allows time for the synthesis of ECM while supporting biomechanical loadings.  
However, a downside to SIS is that it has a rough and smooth side, and cells cannot 





Figure 2. 9: SIS cell seeded scaffolds show significant increase in GAG content in AF 
(A), and NP (B), as compared to non seeded scaffolds in vitro. *p< 0.001, **p< 0.01.176 
 
Studies investigating cell attachment for IVD scaffolds have proven the ability of 
DBM and gelatin to promote cell attachment as compared to PLA alone (Figure 2.10) 173.  
Materials similar to DBM, such as Bioglass®, were also incorporated into an IVD 
scaffold. 3-D PLA foams composed of 0, 5, and 30 wt% Bioglass® particles were tested 
to determine the constructs ability to satisfy the requirements for a tissue engineered IVD 
179. The 30% Bioglass®/PLA composites increased cell proliferation and exhibited 
significantly higher GAG and collagen production as compared to PLA alone 179. One 
downside to the use of DBM and Bioglass® materials, though, are the materials 
compliance and rigidity. This becomes an issue as the scaffold may not have the ability to 
absorb loads in vivo. Also, these biomaterials may not be able to be easily implanted, 




Figure 2. 10: Top: LIVE/DEAD imaging of cells on PLA (A), gelatin (B), and DBM 
(C) scaffolding with diameters of 0.7-1.1 mm, 100-150 µm, and 1-2 mm, respectively. 
Bottom: SEM after 1 month of culture showed that PLA was smooth (A), gelatin had 
interconnected pores (B), while the DBM consisted of an oriented structure (C) 173. 
 
 
Other degradable polyesters besides PLA and PGA, such as polycaprolactone 
(PCL), have also been combined with DBM to increase cell attachment. A scaffold with 
an outer DBM region and oriented layers of PCL in the inner region was used to recreate 
the AF structure (Figure 2.11) 180. The use of DBM improved the compressive and tensile 
strength of the scaffold 180.  However, this scaffold only mimics the AF region, and does 
not attempt to incorporate an integration within the scaffold for a NP region. Although 
cells infiltrated the scaffold and produced matrix, they did not elongate and align in an 
organized fashion like the native tissue (Figure 2.12) 180.  Also, as seen in previous 
studies, the biomechanical properties of the scaffolding construct are not elastic and do 




Figure 2. 11: Safranin-O staining of normal rabbit IVD (a,b). PCL scaffold fabrication 




Figure 2. 12: Scaffolding at different magnifications using safranin-O staining (P: 
PCL, C: Chondrocytes), and collagen type II fluorescent staining (right top: 
cells/scaffold, right bottom: control scaffold) after 4 weeks culture 180. 
 
PCL alone has also shown success in emulating the organized collagen fibers in 
the native AF. For instance aligned PCL nanofibers have been bundled together in order 
to create a single lamella with 1 mm thickness 181. AF cells seeded onto these PCL 
bundles oriented in alignment with the fibers and synthesized matrix 181. Though this 
scaffold provided accurate 3-D microstructure of a single lamellae, this technique needs 
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to be improved by fabricating multiple lamellae within the same scaffold to accurately 
mimic the native tissue architecture 181.  
As can be seen, there have been many materials and structures that have been 
investigated for AF tissue regeneration, yet there has been little evidence of how these 
materials will integrate with the vertebrae. Takahata et al developed a 3-D polymer fabric 
(3-DF), mimicking the shape of the IVD, which was composed of UHMWPE and coated 
the top and bottom surfaces with hydroxyapatite bioceramic granules in hopes of 
promoting vertebral body ingrowth. Animal studies using this 3-DF have demonstrated 
bone growth into the construct, as well as firm fixation to the vertebral body 182. 3-
DF/UHMWPE discs resisted fatigue and their mechanical properties remained constant 
after 2 million cycles of dynamic loading, proving the materials durability 183.  One 
problem with this scaffold design, though, is that it was too rigid and did not accurately 
replicate a biphasic NP and AF region. 
 
Nucleus Pulposus Scaffolding 
As mentioned above, many materials have been extensively used for AF tissue 
engineering applications. Some of these same materials have also been used as NP 
scaffolding materials. For example, PLGA (70:30) scaffolds were used to regenerate the 
NP tissue using a canine animal model 83. Evidence of tissue regeneration by chondrocyte 
type cells and increased ECM was observed after scaffolds completely degraded at 4 
weeks 83. Similarly, a NP replacement composed of biocompatible and incompressible 
polycarbonate urethane has shown to sustain biomechanical loading to maintain disc 
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height after a discectomy 184.  The material consists of a memory coiling spiral which can 
roll into shape after being implanted into the region of the removed NP (Figure 2.13) 184. 
A drawback to the use of polycarbonate urethane is that the AF must be intact and 
healthy to support spinal loads 184.  However, because these materials are not injectable, 
they may damage the AF, which may lead to further disc degeneration. Therefore, a 
material for NP regeneration combined with other scaffolding materials used in AF tissue 
engineering is a more attractive idea to mimic the biphasic IVD composition.  
 
 
Figure 2. 13: Human cadaveric IVD after NP removal (A), and after implantion of 
memory coiling spiral in the NP (B) 184. 
 
Biphasic IVD Scaffolding 
It has been shown that a variety of materials have been used to emulate one region 
of the IVD. However, these materials can be used in conjunction in order to create 
composite structures that mimic the biphasic structure of the natural IVD and 
simultaneously reproduce NP and AF tissue. Composites that use polymers such as PGA 
or PLGA to mimic the AF, and alginate to mimic the NP have been developed 185,186.  In 
one design, a radically oriented PGA mesh combined with an alginate hydrogel has been 
formed into a composite to emulate the AF and NP, respectively. Each of these materials 
maintained their distinct regions after 4 months implantation (Figure 2.14) 185.  Also, this 
scaffold allowed for newly formed NP and AF tissue, which possessed a high intensity 
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safranin-O staining after 12 weeks in vivo, proving the formation of cartilage tissue 186.  
Further, the GAG content and compressive modulus of the PGA-alginate scaffolds 
increased to values similar to native mice IVD levels (Figure 2.15) 185.  In another study, 
PLGA and alginate scaffolds had similar morphology and composition, as well as the 
structure of newly formed tissue, to that of the native tissue 186.  One limitation of these 
particular scaffolds, however, is that the AF region of these materials was not as lamellar 
and organized as the native tissue 186.  Another downside to the use of PLGA or PGA 
with alginate is that the mechanical properties are not as similar to human IVD tissue, 




Figure 2. 14: Top: Both regions of the scaffold encouraged GAG synthesis similar to 
native tissue in mice (left), while the modulus of the scaffolds also increased over time 
to reach values similar to native tissue. Bottom: PLA/PGA and alginate scaffolding 
before implantation (A), and implanted for 4 weeks (B), 8 weeks (C), and 16 weeks (D) 
showing two distinct IVD regions.185 
 
Like alginate, hyaluronan (HA) hydrogels have also been combined with PGA 
scaffolds. Absorbable PGA scaffolds have been combined with fibrin-HA solutions, 
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containing expanded human IVD chondrocytes, and formed IVD-like tissue after 2 weeks 
in culture 160.  In vitro, IVD cells assembled in 3-D on these scaffolds, while passing 
necessary biocompatibility requirements and showing no decrease in cell viability as 
observed by LIVE/DEAD staining (Figure 2.15) 160. Also, collagens and GAGs were 
produced in 3-D culture, on the PGA fibrin-HA materials, however, a more fibrous tissue 
was formed, as collagen type I expression was greater than collagen type II expression 
160. This response was unwanted as collagen type II is more desired in a healthy disc 
regeneration. To expand on the use of PGA and HA, certain groups have used cell free 
nonwoven PGA-HA resorbable scaffolds and immersed them in serum containing growth 
factors in order to attract cells and induce IVD regeneration in rabbit models 159,187.  After 
12 months of implantation, the animals with the scaffold treated discs exhibited extensive 
infiltration of ECM proteins, such as PGs and collagen type II, allowing for an enhanced 
disc height as compared to the controls. This study proved that long term success of 
PGA-HA materials is possible as chondrogenesis was observed, with an increase in PG 
and water content (Figure 2.16) 159,187. Also, the ECM synthesized had a similar 
composition to native tissue and were resorbed completely between 40 and 60 days with 






Figure 2. 15: LIVE/DEAD staining of the cells within the PGA fibrin-HA scaffold at 1 
(A) and 2 (B) weeks. It can be seen in B, that live cells migrated into a more 3-D 






Figure 2. 16: H&E (A,C), and Safranin-O (B,D) staining 12 months after a discectomy 
(A,B) or PGA-HA treated materials(C,D) showing increased cellular infiltration 
(circles) in the implant treated discs and tissue necrosis (arrows) in the controls 187. 
 
 
It has been shown that HA may be an effective hydrogel for IVD regeneration 
when combined with appropriate scaffolds. For this reason, biphasic biodegradable PLA 
nanofiber scaffolds consisting of an HA center have been tested 103.  The electrospun 
nanofibers resemble the native lamellar structure of the AF 103.  During culture, cells in 
the PLA-HA construct elongated and aligned in a concentric fashion on the nanofibers 
while also increasing secretion of GAGs and other ECM content, as evidenced by H&E 
 52
and alcian blue staining (Figure 2.17) 103.  PG staining with alcian blue showed no 
distinct organization within the NP while the AF has a more organized structure, 
mimicking native IVD tissue architecture (Figure 2.17) 103.  One issue with the scaffold, 
though, is that it does not support necessary biomechanical loads 103.  The PLA fibers 





Figure 2. 17: Left: Staining of PLA/HA scaffold showing increase in cellularity and 
PG content in both the AF and NP over 28 days. Right: Quantitative assay showing 
increase in GAG synthesis over time 103. 
 
Natural polymers, such as collagen type I have also been used in conjunction with 
hydrogels in order to create a biphasic IVD scaffold. In one study, a HA hydrogel 
surrounded by collagen type I, at a ratio of 9:1, was used to make a composite scaffolding 
material, which promoted growth and attachment of functional IVD cells for 60 days in 
culture 137.  PGs including aggrecan, decorin, biglycan, fibromodulin, and lumican as 
well as collagen types I & II all accumulated on the scaffold, showing that cells were 
synthesizing matrix similar to that of the native IVD 137. The synthesized biomolecules, 
however, were not consistently retained within the scaffolds and often escaped into the 
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culture media 137.  For this reason, this particular biphasic construct is not effective, as the 
materials should retain and organize matrix molecules into functional ECM in order to 
properly function as an IVD scaffold. 
As evidenced by previous studies, mechanical properties of IVD scaffolds are far 
from satisfactory. Suitable mechanical properties can be achieved, however, with the 
proper design and materials. One group, Gloria et al, created a scaffold with mechanical 
properties that were very similar to those of the natural IVD122. The scaffold consisted of 
poly (2-hydroxyethyl methacrylate)/ poly (methyl methacrylate) (PHEMA/PMMA) 
(80/20 w/w) hydrogel combined with poly (ethylene terephthalate) (PET) fibers 122. The 
scaffolds showed a J-shaped stress-strain curve similar to most soft tissue, and did not 
experience signs of fatigue under dynamic loading 122. Furthermore, acrylate materials 
can maintain a desirable water content of about 75wt% which is comparable to natural 
IVD water content 188. Although the PHEMA/PMMA/PET construct showed superior 
mechanical properties as compared to other biomaterial structures, and is assumed to be 
biocompatible, no data was provided to prove the scaffolds ability to support cell growth 
and direct matrix synthesis 122. Further evidence may show that this material construct 
might be ideal for IVD regeneration. 
 
2.6 Animal Modeling 
 
In order to evaluate the effectiveness of the strategies developed for IVD tissue 
repair and regeneration, it is important to use appropriate animal models. Also, because 
the complete process of disc degeneration is not well understood in humans, animal 
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models have become increasingly important. Animal models can help determine cause 
and effect relationships of different factors that may relate to disc degeneration. For the 
purpose of creating a degenerated disc, induced injury can imitate a degenerated disc 84. 
Different methods have been used to simulate IVD degeneration with most models using 
spines and tails 84. Results from animal studies have suggested that abnormal mechanical 
loading conditions lead to symptoms of a degenerated disc. Using induced degeneration 
in animal models, therapeutic strategies for IVD regeneration can then be evaluated for 
success. If successful in smaller animals, tissue engineered strategies can be further tested 
in larger animals that better mimic nutritional, biomechanical, and surgical applications 
in humans 189. 
Rodent models are necessary to establish the initial success of an IVD treatment 
strategy. Rodent models help determine whether or not a specific regenerative therapy is 
promoting a desired cellular response. In order to evaluate treatment, degeneration must 
be induced. Research has proven that compressive forces can induce degeneration using 
in vivo mouse tail models 190. Degeneration can also be produced by using a needle to 
puncture the IVD 189. After induced degeneration, rat models have been used to test 
regenerative based growth factor therapy by evaluating changes in PG content and 
changes in disc morphology. 
Small animal models, such as rabbits, are used when strategies have proven 
successful in rodent models. Kroeber et al used axial mechanical loading on an in vivo 
rabbit model to produce a degenerated disc (Figure 2.18) 26. This method is the first 
method where disc degeneration was induced and then treatment methods were evaluated 
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in vivo 26. Rabbits spines that were mechanically loaded for 14 and 28 days exhibited a 
significant decrease in disc height, as well as an outer AF structure that became 
disorganized, proving that compression simulated IVD degeneration. PGA implants were 
then tested in the animals with degenerated discs 26. Abbushi et al were the first to 
remove the degenerated disc, using open surgery microdiscectomy, on rabbit animal 
models to test their implanted materials 159. This method is advantageous over other 
techniques as it is a more destructive resection of tissue, better simulating the clinical 




Figure 2. 18: Rabbit animal model of IVD after dynamic compressive loading for 28 
days showed significantly less height (B) than normal (A) 26 
 
One inherent problem with modeling human IVDs is their size compared to 
animal models. Human IVDs are much larger than most rodents and smaller animals, and 
therefore transport of nutrients and wastes is much more difficult in human IVD 84. For 
this reason, more expensive, larger animal models (canines, sheep, porcine, goats) are 
necessary for in vivo studies as diffusion of nutrients to cells in these larger models more 
accurately mimics human IVD circumstances. Canine spines under large compressive 
loads have been used to model disc degeneration 191. Degeneration in sheep and goat 
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animal models has also shown to be advantageous for potential therapeutic strategies as 
their IVDs are similar in size to humans, and their tissue does not naturally repair 192,193. 
Researchers have also investigated porcine models by promoting degeneration and then 
evaluating the effectiveness of a hydrogel containing stem cells to promote viability and 
differentiation towards a chondrogenic phenotype 194. 
Animal modeling in its later stages needs to be geared more towards better 
mimicking a human spine size and biomechanics. The spines and IVD structures of 
primates is highly similar to humans 126. Also, because primates are bipedal, the forces 
acting on their spines better mimic human loading conditions 126. Although primates may 
be essential for studying IVD regeneration strategies in the future, to date most 
researchers have not used primates as models because of ethical issues and high costs.189 
 
2.7 Mechanical Properties 
 
Since animal studies have shown that compressive forces can induce 
degeneration, it seems there may be a correlation and a limit to the loads the IVD can 
support before experiencing degeneration. The ECM of the IVD consistently bears loads 
in the body, and these loads can be assumed to be primarily compressive 195. The IVD is 
a viscoelastic tissue having time dependent responses to loading and experiences 
nonlinear, anisotropic behavior 84,181. Therefore, static and dynamic compressive tests can 
be used as preliminary indicators for the behavior of devices and biomaterial structures 
for potential spinal disc applications.  
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Disc cells are influenced by a variety of mechanical factors such as mechanical 
stress, and osmotic pressure 27.  Mechanical influences that affect disc cell behavior 
include static compression, hydrostatic pressure, and tensile stretch. Each of these 
external stimuli changes the assembly of PGs, and collagen within the IVD. Atypical 
loading on a healthy disc can cause cellular alterations within the disc, which may be 
characteristic of a disease state 51. Though some evidence suggests that normal 
compressive spinal loads may encourage PG synthesis, loading may also alter the matrix 
composition by decreasing the matrix production and degradation, and decreasing cell 
activity 51. Extensive mechanical loads may cause cell death, decreasing the amount of 
cells available to synthesize and turnover stable ECM molecules 196. During extended or 
abnormal loading periods, the IVD may attempt to remodel to better support the loading, 
usually resulting in a degenerated disc 190. 
Because mechanical loading can be both implicated and compromised in a 
degenerated IVD, it is important for biomaterial structure to have similar mechanical 
properties compared to healthy, native tissue. Mechanical integrity, especially under 
compressive stresses, is important for IVD implants and tissue engineered IVD tissues. 
The compressive modulus of the IVD varies in each region.  In the AF, the compressive 
modulus has been reported to range from 0.116-2.3 MPa, while in the NP the 
compressive modulus has been reported to range from 0.003-0.31 MPa.  Therefore, a 
tissue engineered construct should be able to withstand these loads with some safety 
factor involved. It has been stated that the Young’s compressive modulus of IVD 
scaffolds should range from 0.5-5 MPa and the ultimate strength should be at least 8-10 
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MPa 11,38,197,198. The NP and inner AF are deformed less during compression. Because 
each of the IVD regions contains different matrix molecules, the disc has varied 
mechanical properties in each region. In this regard, IVD implants and tissue engineered 
IVD tissues should have distinct mechanical properties in each region. Mechanical 
properties of IVD constructs need to be better characterized as the mechanical properties 
are important for the IVD functions. Dynamic and static compression tests are 
recommended for IVD constructs as the forces on the spine are primarily compressive 131. 
However, for IVD regeneration using biomaterials, biomaterial structures should be able 
to temporarily support limited amount of spinal loads while promoting matrix synthesis, 
as the regenerating matrix will eventually bear the full spinal loads when the implanted 




Worldwide healthcare goals involve the restoration and maintenance of native 
IVD tissue to decrease its economic burden and impact. The degenerated spinal disc is 
one of the most expensive medical problems currently encountered today as it causes 
disability among many people in the aging population 130.  One major hurdle in creating a 
regenerative therapy for the IVD is that its structure is highly unique and has multiple 
distinct regions. The NP is a disorganized conglomeration of collagen type II and highly 
anionic PGs which help attract water to maintain the disc height. On the other hand, the 
AF consists of highly organized collagen type I based lamellar architecture which helps 
prevent bulging in the NP. The distinct structure of each region of the IVD enables the 
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disc to withstand the everyday dynamic forces placed on the spine. Both the AF and NP 
structures are avascular, meaning cellular nutrition is based solely on diffusion, and also 
making repair of the tissue difficult, inevitably resulting in age related disc degeneration. 
It is important to understand disc degeneration prior to determining an effective 
therapy, since a researcher must know which factors are causing the degeneration in order 
to stop it. All of the exact causes of disc degeneration have not been identified, although a 
variety of factors have been implicated, including loss of biomechanical stability, poor 
nutrition, genetic factors, and an increase in degradative enzymes. Disc degeneration is 
accompanied by a decrease in viable chondrocytes and a loss in PG content within the 
matrix followed by dehydration. During IVD degeneration, the disc structure of the NP 
and AF are highly compromised leading to a fibrous and disorganized structure. As disc 
degeneration progresses, the discs ability to support biomechanical forces on the spine 
become compromised. Eventually, the disc becomes unstable, causing an extensive 
perceived pain by the patient.  
Clinically, the only solutions to a patient’s pain resulting from a degenerated disc 
are therapy, rest, and medication. If these treatments are unsuccessful, a patient may 
require the removal of the degenerated portion of the disc, spinal fusion, or an IVD 
implant. Removal of the degenerated tissue does nothing to stabilize the spine and causes 
problems relating to the decrease in disc height which leads to increased disc 
degeneration.  A current solution to a disc removal is spinal fusion which stabilizes and 
restricts motion.  However, fusion creates its own problems as it increases stress 
concentrations on adjacent discs, causing further degeneration. Therefore, the 
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replacement of degenerated or damaged IVD tissue with a permanent implant is an 
attractive alternative to spinal fusion. Current implants help restore patient mobility and 
disc height. However, these implants have their own faults. Current NP replacements 
damage the native AF upon implantation, causing an inflammatory response that will 
eventually promote further tissue degeneration.  Total disc replacements also have 
problems in that they form wear debris and have a large compliance mismatch, leading to 
stress shielding on adjacent vertebral levels.  Another disadvantage to current disc 
replacements is that they do not replicate physiological motion or promote natural tissue 
repair. 
To improve upon current solutions, tissue engineered IVD structures are being 
developed to regenerate the native tissue. The necessity for the development of 
approaches to promote IVD repair and regeneration is evident in the fact that problems 
still exist with current therapies to disc degeneration. Researchers are currently 
investigating different therapeutic methods to promote IVD regeneration, including cell 
based therapies, signaling molecule based therapies, and biomaterial-based regenerative 
therapies. Cell and molecule therapies alone are unlikely to be effective as they will not 
be able to support in vivo spinal loads. Current NP hydrogel regeneration strategies are 
unlikely to be successful as they may damage the AF. Once the AF is compromised, 
some type of scaffold support structure will be necessary to support loads. Therefore, a 
biphasic structure mimicking both the AF and NP is more likely to have a long term 
impact in IVD tissue regeneration due to the inherent mechanical stability they would 
provide. These tissue engineered IVD structures should have a similar structure and 
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mechanical properties to that of the native tissue in order to properly integrate with the 
tissue and resist failure. Scaffolds also have the ability to be coupled with bioactive 
molecules in order to promote tissue regeneration or prevent an inflammatory response, 
while allowing for mechanical stability 133,199,200.   
Tissue engineering is the future for the treatment of IVD degeneration. 
Conventional treatments for IVD degeneration do not meet the requirements to restore 
patient satisfaction. Due to the failures of current therapies and techniques to prevent and 
treat IVD degeneration, new methods are needed. Novel ideas are necessary to propel 
IVD tissue engineering forward, starting with a basic understanding of design criteria. 
Using previous successes and failures in tissue engineering, the regeneration of the IVD 
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3. FABRICATION OF A BIOMIMETIC ELASTIC INTERVERTEBRAL DISC 




 Over 80% of the adult population is affected by low back pain at some point in 
their lives. Surgical procedures are performed on roughly 5% of the population to 
alleviate this pain, amounting to nearly $90 billion in annual healthcare costs 1. 
Degeneration of the intervertebral disc (IVD) causes compression of the spinal nerves 
and adjacent vertebrae, proving to be a primary cause of low back pain. The exact causes 
of IVD degeneration are unknown, but it is thought that natural aging, excessive 
mechanical compression, and biological or genetic factors each play a significant role in 
the degenerative process 2-5. Current methods to alleviate the pain caused by a 
degenerated disc include spinal fusion and artificial disc replacement. Spinal fusion does 
not restore disc function and may cause further degeneration of adjacent IVDs by altering 
the biomechanics of the spine 6. Artificial IVD replacements have recently started to 
gather interest, with two IVD implants currently approved for use in the United States 7,8. 
These implants help replace the degenerated disc and restore some motion; however, they 
cannot sustain compressive forces due to their lack of elasticity. Additionally, current 
implants may produce wear debris and cause stress shielding on the vertebrae, resulting 
in further disc degeneration and eventually implant failure 9. Tissue engineered IVD 
scaffolds may offer advantages over current approaches, including preservation of disc 
 81
height and natural motion while encouraging formation of natural tissue. Additionally, an 
artificially engineered elastic polymeric disc offers a solution to the problems 
encountered with current disc replacements as it would be capable of supporting 
compressive forces on the spine without permanent deformation. 
Many researchers have attempted to fabricate an IVD scaffold, but none have 
completely satisfied critical requirements for both reproducing morphological and 
mechanical properties of native IVD tissue 10-12. However, creating a tissue engineered 
IVD has proven difficult, as its structure is highly unique, containing a highly aligned and 
lamellar annulus fibrosus (AF). Overall, the IVD is avascular with a bean shaped 
structure 13. The AF is a collagen-rich fibrous structure containing between 15-25 
multilayered, oriented concentric layers (lamellae) 14. This lamellar architecture helps 
support the biomechanics of the disc by preventing excessive tensile force from bursting 
the inner IVD while supporting compressive forces on the spine 15. Cells within the AF 
are highly oriented and parallel to the lamellar collagen fibers 16. To our best knowledge, 
no researchers have replicated the microstructure of the AF when designing a tissue 
engineered construct. Because it is vital that a tissue engineered structure closely mimics 
the native morphology of the disc, a scaffold with a similar structure to the native AF, 
containing concentric lamellar layers, would prove to be a significant advancement 
compared to current tissue engineering strategies.  Furthermore, the development of an 
IVD scaffold with mechanical properties similar to those of native tissue are rarely 
investigated. Therefore, a tissue engineered IVD construct that better emulates 
mechanical properties of the native disc will prove advantageous in the future. 
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 A lamellar disc scaffold formed from elastomeric polymers would offer a high 
compliance and allow restoration of natural three-dimensional spinal motions. A lamellar 
construct mimics the natural histological structure found in the outer region of natural 
IVDs and allows a greater surface area for cell adhesion, alignment, and growth. 
Currently, many different techniques have been used to create an IVD scaffold 12,17-20. 
However, none have been able to fabricate a lamellar structure mimicking the natural 
IVD histology. To this end, we created an additive manufacturing technique that 
combines ultra-fine pipettes for liquid polymer extrusion and a freezing stage for the 
solidification of the scaffolds. This scaffold fabrication method permits the use of many 
different polymers and is suitable for creating scaffolds with different three-dimensional 
configurations. This paper will primarily focus on the use of a biodegradable and elastic 
polyurethane (PU) for the application of IVD tissue regeneration, as polyurethane 
exhibits elastic properties similar to natural IVD tissue, and has shown to encourage 
cartilage growth in previous studies 21.  
 
3.2 Materials and Methods 
 
3.2.1 Scaffold Fabrication 
 
A custom-built computer aided manufacturing device integrated with a freezing 
stage was used for this study as shown in figure 3.1. Microsoft Visual Basic was used to 
program the device for three-dimensional scaffold designs. Scaffolds were designed by 
manually programming the device to resemble the native IVD tissue structure as seen in 
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the literature 22. The nozzle tip was made from a calibrated fire-pulled glass injection 
pipette to allow high resolution printing. Specifically, 5 µL glass capillary tubes 
(Drummond wiretrol, Drummond Scientific Company, Broomall, PA) were heated and 
pulled on a micropipette puller (Narishige PC-10, Japan) to have a well-controlled inner 
























Figure 3. 1: Schematic (A) and image (B) of the apparatus using CAD, a temperature 
controlled freezing stage, and micropipettes. The device allowed for control of the X-Y-
Z axes down to micron level resolution, while separately controlling the polymer 




Degradable lysine diisocyanate (LDI, Kyowa Hakko Kogyo Co., Japan) and 
polycaprolactone diol (PCL, Sigma-Aldrich, USA) based polyurethane was synthesized 
and purified similar to techniques used by others 23,24.  Briefly, 1:1 molar ratios of hard 
segment LDI and soft segment PCL were added dropwise into dimethylformamide 
(DMF, Sigma) and stirred for 3 hours.  The resulting polyurethane was then dissolved 
again in DMF at a concentration of 15% w/v under nitrogen gas flow protection and 
stirred overnight. This polymer solution was extruded out of a syringe through an ultra-
fine glass injection pipette. Polymer solution was fed at a flow rate of 0.005 ml/min onto 
a glass collection plate placed on the freezing stage (maintained at -4° C). The 
micropipette tip was positioned approximately 30 µm above the collecting substrate. The 
freezing stage maintained the scaffold resolution by increasing the polymer solution 
viscosity below its freezing point and causing the polymer to harden in place as it was 
extruded out of the pipette tip. Briefly, the scaffold material is solidified through 
temperature convection from the cold stage to the point where the material is extruded 
out of the pipette tip.  When the temperature is finely controlled, the polymer solution 
will solidify upon extrusion after reaching its freezing point and allow the structure to 
support subsequent layer by layer deposition. Thus, the device and freezing stage can 
precisely control the extrusion and resolution of the polymer, therefore allowing the 
creation of custom designed scaffolds.  The approximate build time for each IVD scaffold 
layer was approximately 3 minutes.  After the printing of each layer, the micropipette was 
raised 20-40 µm in the z-direction and the computer program continued to build the next 
layer of the structure. After the printing procedure was done, solidified scaffolds were 
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removed from the freezing stage and freeze-dried for 24 hours to extract the solvent. 
Large ice crystal formation on the freezing stage was avoided, by operating in a low 
humidity environment, because it alters the physical properties of the extruded polymer, 
thereby affecting polymer shape.  
 
3.2.2 Mechanical Properties of Scaffolds 
 
Mechanical testing was used to characterize the compressive properties of the 
scaffolds using unconfined compression experiments.  Scaffolds (5.75 mm in diameter × 
2 mm in height) were compressed at a rate of 1 mm · min-1 using a DMA Q800 system 
(TA Instruments, Delaware, U.S.A.) and stopped at roughly 50% strain (n=4).  
Engineering stress and strain were recorded and evaluated. The compressive tests were 
performed on hydrated samples at room temperature.  Dynamic compression tests were 
completed on the hydrated samples at room temperature at 0.008 Hz up to a compressive 
strain of 65%. Tests were not completed past 65% compressive strain, as previous studies 
have shown that the IVD only experiences roughly 15% compressive strain, and 
compressive testing to 65% ensured the scaffold would perform well under extreme 
conditions 25. Dynamic shear testing was also performed on the scaffolds similarly to 
previous studies on the IVD 26. Dynamic shear properties were measured for 12 samples 
each at 3 compressive strains (15%, 30%, and 45%) using an AR G2 dynamic rheometer 
(TA Instruments).  Briefly, each sample was subjected to a shear strain of 1.5% at 
oscillation frequencies ranging from 0.05 Hz to 1.05 Hz in 0.05 Hz intervals, similar to 
previous dynamic testing conditions on IVDs 27. These frequencies were chosen as they 
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are comparable to normal physiologic loading rates in the IVD 28. Dynamic shear 
properties were measured at 3 levels of compressive strain because the disc is always 
under some degree of compressive force, usually around 15%. Other levels of 
compressive strains, e.g., 30% and 45%, were also tested to account for severe loading 
circumstances.  
 
3.2.3 In vitro cell culture experiments 
 
Scaffolds used for cell culture were sterilized with 70% ethanol for 30 minutes and 
then rinsed 3 times with sterile PBS for 2 hours per rinse. Bovine IVD cells were seeded 
on the scaffolds at a density of 1x105 cells. RPMI 1640 Media with 10% FBS and 1% 
antibiotic/antimycotic solution was changed every other day throughout the study. Cells 
were cultured on the scaffolds for up to 19 days. An alamarBlue® assay to measure cell 
proliferation and viability (Invitrogen, Carlsbad, CA) was performed on every other day 
from day 1 to day 19 to examine the growth and cytocompatibility of IVD cells on 
printed elastic PU scaffolds versus a flat surface control. Briefly, cells were cultured in an 
alamarBlue® and media mixture at a ratio of 1:40, for 4 hours, after which the media was 
removed and absorbance at 570 nm and 600 nm was measured using spectrophotometry.  
 
3.2.4 Morphological Study 
 
Scanning electron microscopy (SEM, Hitachi TM-1000) was used to visualize the 
morphology of the printed scaffold.  All fluorescent and light microscope images were 
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taken using a Leica TCS SP5 AOBS Confocal Microscope (Leica Microsystems Inc., 
Exton, PA, U.S.A.). For fluorescent staining, cells were fixed with 4% paraformaldehyde 
after 3 weeks of culture, and phalloidin 488 and DAPI were used to stain the actin 
filaments and the nuclei of the chondrocytes within the scaffolds, respectively. The 
morphology of the IVD cells was observed to determine if cells were spread out and 
attached to the 3-D scaffolds.  
 
3.2.5 Statistical Analysis 
 
One-way ANOVA was performed on the values of G’(storage shear modulus) and 
G* (complex shear modulus) across the frequency range 0.05-1.05 Hz with a least 
significant difference (LSD) post hoc comparison set at p<0.05 using SPSS 17 statistical 
software (Chicago, USA). The results of the alamarBlue® assay comparing PU scaffolds 




3.3.1 Scaffold Fabrication 
 
The method presented in this paper uses a freezing stage coupled with a custom-built 
additive manufacturing apparatus allowing for the creation of scaffolds with multiple 
layers and lamellar structures using solid freeform fabrication through the extrusion of 
polymer solutions onto a temperature controlled stage.  The freezing stage aided in the 
solidification of the structure at the time polymer solution was extruded out of the ultra-
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fine pipettes through convection of the cold temperatures from the stage to the extruded 
polymer solution. Ultra-fine pipettes allowed for fabrication of scaffolds with similar 
structure to native IVD tissue with the high resolution and reproducibility necessary for 
controlling the scaffold microstructure. Figure 3.2 shows SEM images of the scaffold, 




Figure 3. 2: SEM images of a custom designed and layered PU 3-D scaffold structure 
mimicking the natural shape of the IVD and showing a lamellar structure (A), multiple 
layers of PU stacked in a 3-D structure, proving accuracy and effectiveness of the 
bioprinter, micropipettes, and freezing stage to maintain high resolution in three 
dimensions (B). 
 
3.3.2 Mechanical Properties of Scaffolds 
 
Elastic properties were determined with mechanical analysis of the scaffolds in 
compression and shear. The average compressive stress-strain curve is shown in figure 
3.3A. The scaffolds showed a J-shaped stress-strain curve, observed in soft tissues similar 
to the IVD. The initial compressive storage modulus (E’) in the toe region was 45.4 ± 5.6 
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KPa (mean ± the standard error of the mean), while the compressive modulus (E’) of the 
linear region was 350 ± 19.6 KPa. These values correspond to similar tests carried out on 
native IVD tissue 28,29. The shape of the curve indicates that the scaffolds significantly 
stiffen under large strains (greater than 40%). Elastic hysteresis was observed in the 
scaffold during dynamic compression (figure 3.3B). Scaffolds did not show permanent 
deformation after 5 cycles of compressive loading up to 65% strain, which is significantly 
more strain than native IVD tissue typically undergoes during loading, proving the 
scaffolds can handle deformation well 25. Aside from basic compressive testing, 
compressive shear testing to 1.5% strain was also carried out as the native IVD undergoes 
shear deformations 26. During compressive shear tests, compression at 15%, 30%, and 
45% strain were used, as compressive strains of around 15% are similar to normal 
physiologic compressive strains 25,30. The storage shear modulus (G’) represents the 
elastic stored energy of the scaffold material. The dynamic shear modulus (G*) is 
comprised of both G’ and G” (energy lost as heat) and can provide important information 
as a material property.  The printed PU IVD scaffolds displayed significant elastic 
responses, during shear tests, in which G* was primarily governed by G’. One-way 
ANOVA was performed across each frequency for G*, G’, and G’’ with compressive 
strain serving as the comparison factor. All of the dynamic shear properties were 
dependent both on the frequency and the compressive strain. Increases in compressive 
strain resulted in increases for G*, G’, and G’’. Increasing the frequency also increased 
the compressive dynamic shear properties, but this was not found to be significant. The 
compressive strain effect was found to be significant for G*, G’, and G’’ (p<0.05) as 
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shown in Table 3.1. Since the material displayed primarily elastic behavior, the trends for 
G’’ are not shown in figure 3.4 due to the minor contributions to G*. During shear 
testing, all recorded frequencies between 0.05-1.05 Hz were analyzed against the 
compressive strains and showed significant differences between all strains with p-values 
all below 0.02. At a frequency of 1.0 Hz, compressive dynamic shear moduli were 57 ± 
23.7 KPa, 97 ± 15.2 KPa, and 135± 12.6 KPa for 15%, 30%, and 45% compressive 
strains, respectively. At a frequency of 1.0 Hz, compressive storage shear moduli were 
56.7 ± 23.7 KPa, 96.5 ± 15.2 KPa, and 134± 12.4 KPa at 15%, 30%, and 45% 
compressive strains, respectively. Figure 3.4 validates that energy is primarily stored by 
the material during deformation, as G’ and G* are highly similar, proving the material 
has significant elastic behavior. Furthermore, our results were very similar to other 






































Figure 3. 3: (A) Stress-strain curve showing average behavior of printed PU IVD 
scaffolds.  Scaffolds exhibited elastic behavior, showing a J-shaped stress-strain curve 
typically observed in soft tissues like the IVD. (B) Representative dynamic compressive 
testing on PU IVD scaffolds which exhibited elastic hysteresis, and did not show 
permanent deformation after multiple cycles of dynamic compressive loading. 
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Table 3. 1: Statistical analysis for Dynamic Shear Moduli at 1 Hz between Compressive 
Strains of 15%, 30%, and 45% (n=12). 
 
Variation Mean (KPa) The standard 
error of the mean 
(KPa) 
Significance 
15% 56.65 23.74 
30% 96.5 15.16 
Storage 
Modulus 
(G’) 45% 133.9 12.55 
p<0.05 
15% 6.51 1.97 
30% 9.55 1.27 
Loss 
Modulus 
(G’’) 45% 13.09 1.63 
p<0.05 
15% 57.03 23.77 
30% 96.96 15.2 
Dynamic 
Modulus 






























































































Figure 3. 4: Mean values of the storage modulus G’ (A), and the dynamic shear 
modulus G* (B) at a fixed shear strain of 1.5% over the frequency range of 0.05-1.05 
Hz.  Samples were tested at compressive strains of 15%, 30%, and 45%, and storage 
shear moduli was found to significantly increase with increasing strain. 
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3.3.3 In vitro evaluation 
 
The scaffold presented a structure which promoted IVD cell attachment and growth 
on the elastic lamellar scaffolds as shown in figure 3.5. Chondrocytes aligned along the 
concentric lamellae proving the ability of the scaffold to promote a desired cell response, 
as cells in the native IVD are highly aligned along the lamellae. The elastic materials 
used to create the scaffold were found to be biocompatible and promoted cellular 
proliferation. An alamarBlue® assay was used to determine cell viability on the scaffold 
constructs by measuring metabolic activity of the cells.  After 19 days in cell culture the 
cells proved to remain more viable on the PU scaffold constructs compared to the 2D 
culture (figures 3.5 & 3.6). The data presented shows the average of 12 samples ± 
standard error of the mean.  There was no negative effect on cell viability of the printed 
IVD scaffold as compared to the tissue culture polystyrene.  Additionally, scaffold 
degradation did not affect cell viability or proliferation since the material we developed 
has a degradation profile for 5-6 months.  Table 3.2 shows that on days 13, 17, and 19 
increased cell proliferation was observed on the PU scaffolds which was significantly 
different from the control wells (p<0.05). It should be noted that cell proliferation 
decreased after day 15. This is probably due to the fact that the cells had reached 
confluence.  In some of the control wells, the confluent cells contracted into ball like 

















































Figure 3. 5: Normalized % reduction graph using AlamarBlue cell metabolic assay 
showing cytocompatibility of PU scaffolds (n=12) compared to the control (n=12). 
Average of control wells was normalized to 1, and the PU scaffolds were compared at 
















































Figure 3. 6: Chondrocyte viability measured using metabolic AlamarBlue assay. 
Comparable proliferation and viability of chondrocytes were found on printed PU IVD 
scaffolds and tissue culture polystyrene wells (Annotation ‘*’ indicates samples were 




Table 3. 2: Statistical analysis for Normalized % Reduction of AlamarBlue Metabolic 
Cell Assay for Cytotoxicity (n=12). 
 
Variation Mean (%) Standard Deviation (%) Significance
PU 106.39 3.97 
Day 13 
Control 100 4.19 
p<0.05 
PU 137.45 3.23 
Day 17 
Control 100 1.85 
p<0.05 
PU 119.45 4.05 
Day 19 




3.3.4 Morphological Study 
 
 Using our device, elastic polymers were deposited onto a freezing stage using 
extrusion to form lamellar structures mimicking the natural structure of IVD tissue as 
shown in figure 3.7. Polymer extrusion can be controlled precisely up to a micron level 
resolution.  Figure 3.2 shows that concentric layers were created with spacing ranging 
from 20µm to 200µm for the accommodation of cells while allowing room for 
extracellular matrix proteins to be secreted. Additionally, cells preferentially aligned 
along the scaffold structure, showing comparable morphology to native IVD cell 




Figure 3. 7: Top view of the scaffold showing viable cells across the entire lamellar 
structure, with cells attaching to the entire scaffold (A), inside view of 3-D scaffold, 
proving cell infiltration into the inner lamellae (B). It can be seen that spacing can be 
accurately controlled to allow the migration of cells into the lamellae. Cells within the 





The bioprinting apparatus described permitted the use of multiple solution based 
polymers and showed the capacity to use both natural and synthetic materials. The 
freezing stage allowed for fast solidification of the polymer solution and could maintain 
temperatures from -40 °C to room temperature, allowing the rate at which the polymer 
solidified to be precisely controlled. The method used in this paper proved the capability 
to control both micro and macrostructure of material constructs using computer aided 
design. For comparison, the compressive storage moduli of the scaffolds appears to be 
sufficient for the repair of the outer region of the IVD as our experimental values (350 
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KPa) are within the range of 220-540 KPa previously reported in the literature for native 
IVD tissue 29.  However, compressive loads were on the low spectrum of physiologic 
values. We expect that when cells grow into the scaffold and will produce extracellular 
matrix to further improve the compressive loading capability.  The scaffold created 
provides elastic properties while mimicking the natural shape and morphology of the 
IVD, as the outer region of the scaffold consists of layered, elastic PU forming concentric 
lamellae.   
The scaffolds fabricated using this technique exhibited elastic properties which may 
help increase natural motion while also absorbing loads within the spine. Dynamic shear 
mechanical data was specifically analyzed at 1 Hz because this value is similar to 
frequencies observed during common everyday activities. Although frequencies may 
increase up to 10 Hz, this is highly uncommon 28,32.  Dynamic viscoelastic analysis of the 
scaffolds proved the elastic nature of the degradable PU.  For comparison, the 
experimental values of G’ (56.7 KPa) and G* (57 KPa) were slightly larger than the 
reported native IVD tissue values of 5.8 and 7.4 KPa, respectively 26.  However, the 
experimental value of G” (6.5 KPa) was almost identical to the reported value of 5.2 KPa 
26.  This analysis leads to the interpretation that the material used here is slightly more 
elastic than the native IVD tissue.  The cyclic compressive shear moduli of the material 
increased with compressive strain and also frequency, proving the effectiveness of the 
scaffold to respond to large loads. An increase in stiffness under large stresses is a 
common feature of the IVD, possibly preserving disc structure under larger loads to help 
maintain cell viability.  The primary effect of G’ during shear testing indicates that the 
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governing component of this scaffold material is the elastic portion. Values of the loss 
tangent (tan delta) were not significantly different between compressive strains, 
indicating that the ratio of stored energy to dissipated energy remained relatively constant 
at increased strain (data not shown). 
Many previous studies have attempted to fabricate a suitable IVD scaffold, but none 
have accounted for the complex lamellar structure of the annulus fibrosus in the outer 
IVD region. This study uses a specialized biofabrication method to create scaffolds with 
very similar structure and overall shape of native IVD tissue. This study also highlights 
the importance scaffold microstructure plays in guiding cell behavior through cell-matrix 
contact. Chondrocytes seeded onto the scaffolds directly infiltrated into the lamellae. 
Eventually, the cells began to elongate along the layers of the scaffold.  After 19 days in 
culture, the chondrocytes form an aligned cell structure similar to that observed in native 
IVD. Throughout this culture period, the scaffolding material did not yet begin to 
degrade. Results from cytotoxicity and cell viability assays indicate that this material is 
non-toxic and serves as an excellent scaffold choice for further investigations into IVD 
regeneration. In another study to evaluate the degradation of our LDI-based PU, we 
found that the degradation products are not toxic to cells. This study serves as proof that 
the future of IVD tissue engineering will rely on the ability and successes of researchers 
to properly design and fabricate scaffolds that satisfy the requirements of matching native 





 This is the first study to use a freezing stage to control the resolution of a three 
dimensional additive manufacturing device for the fabrication of an IVD scaffold. An 
advantage of this technique is the ability to successfully reproduce large quantities of 
tissue scaffolds. By combining ultra-fine micropipettes and a freezing stage, the 
resolution of the apparatus can be greatly improved. The use of the freezing stage 
effectively allows a high resolution design down to the micron level. With the freezing 
stage, structure of the scaffold can be controlled precisely allowing for control over cell 
morphology. Multiple facets were investigated prior to the creation of the scaffold 
including: motor speed, polymer extrusion rate, polymer concentration, and freezing 
stage temperature. The spacing between the subsequent layers of the printed elastic 
scaffolds is mimetic to the natural IVD and the spacing allows room for cell attachment 
while providing space for ECM deposition within the scaffold and ultimately creating a 
favorable structure to promote IVD regeneration. The biodegradable PU scaffolds 
exhibited superb elastic properties under compression, proving the construct to be an 
ideal material for IVD tissue regeneration. Furthermore, during compressive shear testing 
at physiological frequencies, the scaffolding constructs behaved similarly to native IVD 
tissue, proving their effectiveness to emulate native IVD biomechanics.  Future studies 
will be carried out over a longer time period to determine how scaffold degradation 
affects both cell viability and mechanical properties. 
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4. FABRICATION OF AN ELASTIC LAMELLAR SCAFFOLD USING RAPID 
PROTOTYPING FOR INTERVERTEBRAL DISC REGENERATION 
 
4.1 Introduction  
 
Low back pain, which affects over 80% of the adult population at some point in 
their lives, accounts for 5% of all surgical procedures, amounting to nearly $90 billion in 
annual costs 1. One primary cause of low back pain is the degeneration of the 
intervertebral disc (IVD), which results in the compression of the spinal nerves and 
adjacent vertebrae 2.  Exact causes of degeneration are unknown, but it is thought that 
natural aging, biological and genetic factors, and mechanical stimuli may play a 
significant role in the degenerative process 3-6.  Conventional methods to alleviate this 
pain include spinal fusion and artificial disc replacement, neither of which restore natural 
kinematics within the spinal column 7-11.  As an alternative to these conventional 
approaches, tissue engineered IVD constructs offer the advantage of biointegration while 
preserving the essential attributes of natural motion and disc space restoration. The use of 
elastic polymeric artificial discs to mimic the mechanical properties of the native IVD 
offer a solution to some of the problems encountered with current disc replacements. 
The IVD is the soft and tough fibrocartilage disc that is sandwiched between 
adjacent vertebrae in the spine. This tissue functions as: 1) a ligament that holds the 
vertebrae of the spine together; 2) a shock absorber; and 3) a “pivot point” that allows the 
spine to bend, rotate, and twist.  The IVD is composed of three structures: the nucleus 
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pulposus (NP), the water-rich gelatinous center that primarily bears the pressure; the 
annulus fibrosus (AF), the collagen-rich fibrous structure of 15~25 concentric sheets of 
collagen (lamellae) that confines the pressurized nucleus; and the vertebral end-plates 
(VEP), which are cartilaginous plates that are interwoven into the annulus at the disc-
vertebrae interface and supply nutrients to the disc 12. Chondrocyte-like disc cells reside 
in all three of these structures. The disc is kidney shaped and avascular, making natural 
regeneration difficult 13.  
The current study focuses on the fabrication of structures that precisely mimic 
every facet of the AF, as the complex tissue architecture of this region has posed great 
challenges to researchers.  This is most likely due to their inability to closely match the 
biological function, microstructure, and mechanical properties of the intricate AF.  This 
region is a lamellar structure composed of collagen type I and II fibers, which maintain 
the tensile properties and prevent mechanical bulging of the disc, while also providing 
support for cell guidance and proteoglycan synthesis 14. Cells within the AF are oriented 
in alignment with the lamellar collagen fibers 15. It has been shown that cell alignment 
can be guided in accordance with a scaffold, as aligned substrates have been shown to 
influence cell morphology 16,17.  This is highly important for an IVD scaffold, in order to 
allow chondrocytes to spread out, align, and organize their cytoskeletons similar as in the 
native tissue 18,19. In addition, aligned cells usually generate highly organized ECM in the 
direction of cell orientation 18,20.  This increase in cell orientation and ECM production on 
aligned substrates has also been shown to significantly increase the mechanical strength 
of the scaffolds 21. From this data, it can be seen that a tissue engineered scaffold that 
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closely mimics the native architecture of the disc as closely as possible, which contains 
highly ordered lamellar layers, would demonstrate a major advancement compared to 
current IVD scaffold fabrication methods.  
Few scaffold fabrication techniques have allowed for the reproducibility and 
spatial control over IVD scaffold design that rapid prototyping permits. However, 
electrospun nanofibers and other materials have been created to mimic the AF 22,23.  
These scaffolds do not have the ability to be fabricated in a spatially controlled manner. 
Furthermore, few researchers have investigated the fabrication of IVD scaffolds with 
similar mechanical properties to the native disc.  The mechanical integrity of the IVD is 
very important because it aids in maintaining spinal column height.  The elastic nature of 
the IVD also allows the disc to absorb large compressive loads without permanent 
deformation. Therefore, we aim to reproduce an elastic IVD scaffolding material that 
better mimics natural IVD morphology and biomechanics. 
The scaffold fabrication technology presented here uses a freezing stage coupled 
with a custom-made rapid prototyping apparatus to fabricate scaffolds that mimic the 
native IVD microstructures with high reproducibility. Additionally, this rapid prototyping 
setup enables the creation of patient specific scaffolds to make the technique more 
clinically relevant.  The device extrudes polymer solution onto a freezing stage to create 
scaffolds through a layer-by-layer process, also termed “additive manufacturing” 24-27.  
The freezing stage increases the polymer viscosity and solidifies the solution as it is 
extruded out of ultra-fine micropipettes, allowing the device to maintain a high 
resolution. In this study, a degradable chitosan/gelatin (Chs/Gtn) solution was used to 
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create an IVD scaffold that provides elastic properties, and promotes IVD cell adhesion 
and proliferation in alignment with the lamellar region.  In addition to mechanical 
properties, the scaffold was designed in CAD to mimic the native AF, forming concentric 
lamellae in a kidney-like shape. Currently, we are not aware of any research claiming to 
have replicated IVD shape, microstructure, and the mechanical properties of the AF when 
fabricating an IVD scaffold or construct.  
There is a great need for the development of tissue engineered scaffolds that 
simulate the natural 3-D morphology and microenvironment of targeted tissues. Many 
researchers have investigated tissue engineering applications to fabricate IVD scaffolds. 
However, the majority of studies on IVD tissue regeneration fail to simultaneously 
account for both biomechanical properties and natural tissue morphology, both of which 
are imperative for the success of an IVD scaffold 28-30. The close correlation between the 
biological function and the molecular composition of the disc structures strongly suggests 
that a major task of IVD regeneration is to create scaffolds that precisely reproduce the 
structural and biological functions of disc structure. In this study, we aim to fabricate 
IVD scaffolds with the similar microstructures and mechanical properties as the native 






4.2 Materials and Methods 
 
4.2.1 Rapid Prototyping Device  
 
A rapid prototyping instrument was developed in our lab in order to fit the 
specific needs of this study (Figure 4.1). The motion controlling hardware and software 
were specially designed to fabricate scaffolds that mimic the AF region of the IVD. 
Microsoft Visual Basic was used to program the controlling software and control the 
motors and dispensers. AutoCAD was used to design the scaffolds mimicking the 
patterns of IVD lamellae. Micropipettes with 25 µm inner diameter were used as printing 
tips. A freezing stage (model BFS-30MP, Physitemp Inc., Clifton, NJ) with a finely tuned 
temperature control was used for fast freezing of the dispensed polymer solution into 3-D 




Figure 4. 1: The home made computer-controlled rapid prototyping apparatus with 
temperature-controlled stage for 3-D IVD scaffold printing. 
 
4.2.2 Polymer Synthesis 
 
Light curable, biodegradable, and biocompatible chitosan/gelatin (Chs/GEL) 
materials were created using a method developed in our lab for cartilage tissue 
regeneration 31. Briefly, 5% gelatin was dissolved in dimethyl sulfoxide (DMSO) and 1% 
Irgacure 2959 (obtained from Ciba Specialty Chemicals) was dissolved separately in 
DMSO.  75 mg of methacrylate modified photocurable chitosan was mixed with 0.5 mg 
of Irgacure solution and added to 1.05 g of the gelatin/DMSO solution and dissolved for 
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10 minutes.  The resulting solution was then used to fabricate the IVD scaffolds using the 
homemade bioprinter.  
 
4.2.3 Scaffold Fabrication 
 
Scaffolds were designed to replicate the natural IVD shape and histological 
morphology, as detailed in the literature (Figure 4.2) 32.  The polymer solution was 
dispensed using a syringe pump (Kent Scientific, Torrington, CT) at a flow rate of 0.005 
ml/min.  The polymer solution was fed through a glass micropipette tip and deposited on 
the freezing stage, which was set at 0° C. The approximate build time for each scaffold 
layer was around 5 minutes.  After printing a layer, the micropipette was raised 50 µm in 
the z-direction and continued to lay the next layer.  After finishing printing the whole 
structure, the freezing stage was powered off and ultraviolet light was exposed to the 
printed structure for 10 minutes to further solidify the scaffolds. The scaffolds were then 
frozen again and subjected to freeze-drying for 24 hours to extract the solvent.  After 
lyopholization, scaffolds were rinsed with phosphate buffered saline (PBS) 3 times and 
then sterilized in 70% ethanol for 30 minutes, followed by 3 more rinses in sterile PBS. 
 
 
4.2.4 Isolation and Culture of Chondrocytes on the 3-D Scaffolds 
 
The IVDs of 4 to 5 month old calves were surgically removed and digested in 
order to isolate the IVD chondrocytes. The primary bovine IVD chondrocytes were 
cultured to passage 2 and then seeded on the scaffolds at a density of 1.25 x 104 
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cells/scaffold to examine their growth on the printed constructs. The IVD constructs were 
incubated at 37 °C and 5% CO2 for 10 days before fixing  in 4% paraformaldehyde and 
staining with AlexaFluor 488 Phalloidin (Invitrogen, Carlsbad, CA), for the actin 




Scanning Electron Microscopy (SEM, Hitachi TM-1000, Tokyo, Japan) was used 
to visualize the morphology of the fabricated scaffold. All microscope images of 
fluorescently labeled cells were taken using a Leica TCS SP5 AOBS Confocal 
Microscope (Leica Microsystems Inc., Exton, PA). The morphology of the cells was 
observed to determine if cells were attached, spread out, and aligned on the 3-D 
scaffolds.  Images were then compared to native IVD tissue structures from the literature.  
 
4.2.6 Mechanical Testing 
 
Mechanical properties of the scaffolds were characterized using unconfined 
compression tests on hydrated samples at room temperature. IVD scaffolds (5.75 mm x 
1.75 mm, diameter x height) were compressed at a rate of 1 mm/minute using a Dynamic 
Mechanical Analysis (DMA) Q800 system (TA Instruments, New Castle, DE) and 
discontinued at 45% strain.  As previous studies have shown the IVD to experience 
roughly only about 15% compressive strain 33-35,   compression to 45% accounted for 
loading of the scaffolds under extreme conditions. Afterwards, the engineering stress and 
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strain were evaluated while the compressive elastic modulus was calculated from the data 
of the stress-strain curves. Additionally, unconfined dynamic compression tests were 
completed for 7 cycles at a rate of 1 mm/minute over the range of 30-45% compressive 
strain. These strains were used as they simulate strains that are slightly larger than normal 
physiological loads, which prove the ability of the material to recover under abnormal 
conditions 36,37. Dynamic experiments were also performed on the scaffolds, similar to 
previous studies 37. Dynamic confined compression was used to compare the behavior of 
the scaffold material with native human IVD tissue at physiological frequencies. Briefly, 
5 mm diameter hydrated samples were compressed to 10% strain and then dynamically 
compressed with amplitude of 1 µm using a frequency sweep ranging from 0.25 Hz to 5 
Hz. This compressive strain and frequency range both simulate normal physiologic 
loading conditions within the IVD 33,38,39.  The values of G’ (storage moduli), G’’ (loss 
moduli), G* (complex moduli), and tan δ (phase angle) were all recorded and analyzed. 
All samples were tested in triplicate and represented as average ± standard deviation. The 
load cell readings were recorded on a computer and analyzed with TA Universal Analysis 
2000 Software (TA Instruments, New Castle, DE). 
 
4.2.7 Statistical Analysis 
 
One-way ANOVA was performed on the values of G’, G’’, G*, and tan δ across 
the frequency range of 0.25 Hz to 5 Hz to compare the IVD scaffolds with the native 
human IVD tissues. A least significant difference (LSD) post hoc comparison set at 
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4.3.1 Scaffold fabrication  
 
 Using the customized 3-D bioprinter (Figure 4.1), elastic Chs/Gtn polymers were 
fabricated into lamellar structures mimicking the natural shape (Figure 4.2A) and 
microstructure (Figure 4.2B) of the IVD. The video for the high resolution IVD scaffold 
printing process can be viewed from the supplemental materials section. The custom 
micropipettes enabled the fabrication of scaffolds with high resolution and concentric 
layers, having a thickness of 50-100 µm, with spacing of 100-200 µm for the 
accommodation of cells (Figure 4.3 & 4.4) 40-42.  The freezing stage allowed for fast 
solidification of the polymer solution and maintained the polymer solution viscosity, 
making it ideal for scaffold shape retention. In figure 4.3 and 4.4, it can be observed that 
cells lined along the scaffold patterns and migrated into the voids between the concentric 
lamellae, demonstrating the efficacy of this scaffold in mimicking the structure of the 
ECM and guiding the cellular organization of the native IVD. This is confirmed by 
comparing the structure of our fabricated scaffolds (Figure 4.4 A&B) with native IVD 







Figure 4. 2: Top-view image of the multilayered IVD scaffold, showing that the 
structure mimics the kidney shape and the organization of the concentric lamellar 
microstructures of the natural IVD (A).  High magnification SEM image of the 
Chs/Gtn scaffold lamellae stacked in multiple layers, proving the efficacy of this 
technique to create layered structures in 3-D while accurately controlling spacing 








Figure 4. 3: Cells aligned along the 3-D Chs/Gtn IVD scaffold structure (A), higher 
magnification image showing cell elongation and alignment along lamellar scaffold 
(B). Actin filaments and nuclei stained in green and blue, respectively.  3-D rendering 
of cells on scaffold from Figure 4.3A (C). Cells and actin cytoskeleton are shown in 








Figure 4. 4: Top view of the 3-D scaffold showing aligned IVD chondrocytes inside the 
scaffold, demonstrating cell infiltration into the inner lamellae (A), higher 
magnification image of cells aligned along lamellae (B), and cells in natural IVD 
tissue for comparison  (C).  Actin filaments are stained green (A-C), while nuclei are 
stained blue (A,B), and orange (C). 32 
 
4.3.2 Culture of Chondrocytes on the 3-D Scaffolds 
 
The fabricated constructs resembled the native IVD architecture and shape, 
containing a highly ordered outer AF region, while emulating the elastic nature of the 
native IVD. Cells grew well on all of the scaffolds, confirming preliminary results 
demonstrating excellent biocompatibility 31.  Bovine IVD cells attached, migrated, and 
spread uniformly on and within the lamellar scaffolds, while proliferating in three 
dimensions (Figure 4.3 & 4.4).  The designed 3-D scaffold increased the surface area of 
the construct allowing cells to attach and conform to the native tissue architecture. The 
cells became elongated and became layered in a concentric fashion similar to the native 
AF (Figure 4.3 & 4.4).  This preferential cell alignment exhibited comparable cell 




4.3.3 Biomechanical Analysis 
 
The average compressive elastic modulus for the toe region, at <5% strain, was 
0.101 ± 0.03 MPa, while the average elastic modulus for the elastic region, at >15% 
strain, was 0.31 ± 0.018 MPa (n=7).  A representative stress-strain curve of the scaffold 
can be seen in Figure 4.5. There was no evidence that sustained compressive forces 
negatively affected scaffold thickness, as no permanent deformation occurred in samples 
compressed to 45% strain. This larger strain, compared to the typical 15% compressive 
strain that the IVD normally experiences, was used to validate the efficacy of the Chs/Gtn 
scaffolds in maintaining its ability to support extreme or abnormal loading 33-35. The IVD, 
like other soft tissues, exhibits a J-shaped stress-strain curve similar to the curve shown in 
Figure 4.5, representing the Chs/Gtn scaffolds. Elastic hysteresis of the scaffolding 
material was observed after dynamic compressive loading, as seen in Figure 4.6. After 3 
cycles of preconditioning, repeatable cycles were achieved where the material showed 
elastic properties. Scaffolds demonstrated the ability to resist fatigue over time, therefore 
proving an excellent choice as a disc replacement material. These results confirm that the 
elastic scaffold has ideal properties to absorb forces and recover without experiencing 
significant deformation.  The Chs/Gtn scaffolds and native tissue were tested using 
dynamic physiological frequencies around 1 Hz across a range from 0.25 to 5 Hz (Figure 
4.7).  Specifically, G’, G’’, G*, and tan δ were analyzed for both samples, and the results 
indicated that the scaffolding material behaved very similar to native human IVD tissues. 
As seen in figure 4.7, energy is primarily stored by the material during deformation, as G’ 
 116
and G* values between the scaffold and tissue are very similar, demonstrating that native 
IVD tissue and the scaffolding material are significantly governed by elastic properties. 
No significant difference was seen between the mechanical properties of the native tissue 
and scaffolds (Table 4.1), indicating that the scaffolds are suitable for use as an IVD 
























Figure 4. 5: Representative compressive stress-strain curve showing a J-shaped curve 



























































































Figure 4. 6: Representative dynamic compressive loading curve of the Chs/Gtn IVD 
scaffold. For the displacement of 30% to 45% (A), scaffold size was not altered after 
compressing (B), and the scaffolds were able to maintain constant forces, proving that 












































































































































Figure 4. 7: Graphs showing very similar average G’ (A), G’’ (B), G* (C), and tan δ 
(D) of human IVD tissues and IVD scaffolds (n=7). Samples were tested across a 





Table 4. 1: At a physiological frequency of 1 Hz, there was no significant difference in 
mechanical properties (G’, G’’, G*, and tan δ) between the scaffolds and the native 
IVD tissues. Data is shown as average ± standard deviation. 
 
 Storage 










401.6 ± 191.8 77.3 ± 45.1 409.3 ± 196.1 0.188 ± 0.055 
Scaffolds 
(n=7) 





One hurdle in the field of regenerative medicine is to create a method to fabricate 
tissue scaffolds that can be translated clinically for a variety of patients.  The rapid 
prototyping technology developed here incorporates a customized scaffold design, 
enabling the creation of patient-specific tissue engineered constructs. Current disc 
replacement strategies do not account for biological growth or integration when 
compared to the native IVD. Furthermore, previous scaffold fabrication methods aimed at 
overcoming the shortcomings of spinal fusion and the current disc replacements fail to 
address the importance of replicating scaffold microstructure and biomechanics. 
Therefore, a rapid prototyping approach was developed in which 3-D scaffolds with 
morphological, biological, and mechanical properties similar to those of native IVDs 
could be produced. This method provides a way for 3-D scaffold formation through 
layer-by-layer fabrication in a reproducible and cost effective manner.  
A lamellar disc scaffold formed from elastomers would offer much better 
compliance and may allow the restoration of natural three dimensional spinal motions 
compared to current disc replacement options. The novel scaffold with lamellar structures 
closely mimics the histological structure found in the AF portion of native IVDs. 
Lamellar structures also allow a greater surface area for cell adhesion and growth. 
Currently, many different techniques have been used to fabricate scaffolds for IVD 
regeneration; however, few have been able to fabricate the complex lamellar structure 
that is unique to natural IVD architecture.  The ability of our bioprinted scaffold to mimic 
the lamellar pattern, thickness, as well as the spacing between the lamellae within the 
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native IVD, corresponds with data supported by the literature for both the layer thickness 
as well as the interlamellar spacing 40-42. Furthermore, this study shows the ability to 
guide cell organization on a scaffold mimicking IVD microstructure by controlling 
scaffold microstructures. To this end, we used a bioprinting-based rapid prototyping 
technique that combines ultra-fine micropipettes for liquid extrusion and a freezing stage 
for the fast solidification of the biomimetic scaffolds. As the polymer solutions solidify 
rapidly, the scaffold becomes self supporting and supports the addition of new layers and 
the creation of 3-D structures. This method is highly valuable as it allows for the use of 
many different polymer solutions and can reproducibly create scaffolds with varying 3-D 
configurations and definitive microstructures.  
The scaffolds created mimic the native IVD structure while promoting cell 
attachment and viability. Chondrocytes attached and aligned in the direction of the outer 
lamellae, similar as in the native structure of the IVD.  When mimicking the highly 
organized native IVD, it is important that the lamellar IVD scaffold transforms cells into 
an aligned configuration.  This aligned configuration will translate into the production of 
ECM in alignment with the fabricated scaffold as evidenced by other studies using 
oriented substrates to increase matrix deposition 18,19,44.  Scaffold images show a structure 
in which cells could attach, proliferate, and create ECM necessary for maintaining IVD 
function 45-47. Space for aggrecan production is extremely important in the IVD as their 
hydrophilic properties help the disc material retain water and remain healthy and 
functional.  In addition, cellular synthesis of aligned matrix within the material will 
further increase the mechanical properties of the scaffold 21.  
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The 3-D elastic Chs/Gtn scaffold showed superb deformability while having the 
ability to be press fitted in between the vertebrae. Large compressive stresses can be 
achieved without the polymer scaffold material failing.  Furthermore, the compressive 
moduli of the scaffold correlates with properties of normal IVD tissue reported in the 
literature, proving the efficacy of our scaffolds in satisfying native disc biomechanics 
requirements 39,48,49.  Dynamic testing proved that the scaffolds could handle large 
deformations, accounting for extreme physiologic circumstances. Additionally, the 
material remained elastic under higher physiological frequencies. Dynamic mechanical 
data was specifically analyzed at 1 Hz because this value is similar to frequencies 
experienced in humans during common everyday activities 50.  These dynamic loading 
tests validated these scaffolds as suitable IVD disc replacements, as both the native tissue 
and scaffolding material had similar properties as well as were both governed by the 
storage modulus (G’).   
The IVD has a limited potential to regenerate because it is avascular, making IVD 
degeneration a difficult therapeutic target and a challenging task for tissue engineering. 
Current surgical remedies to solve the problem of disc degeneration do not address the 
need for a regenerative therapeutic based material design. An elastic, degradable polymer 
based scaffold that is biocompatible and can preserve natural 3-D kinematics within the 
spine is needed. The novel biomaterial scaffold design discussed in this paper mimics the 
AF architecture of the native IVD by successfully reproducing the lamellar nature of the 
disc.  Furthermore, this scaffold is advantageous over other IVD therapies as it replicates 
natural IVD tissue biomechanical properties. The technique described utilizes a method 
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that may help regenerate the unique IVD structure for future applications by matching 
native tissue structure and biomechanics. Also, as this method of rapid prototyping does 
not use high temperatures, it allows for drug encapsulation and has the ability to use a 
broad variety of biomaterials, making it an ideal candidate for a wide variety of future 




The development of a computer-aided tissue engineering platform for IVD 
regeneration is a challenging task.  This study focused on using a rapid prototyping 
technique to fabricate IVD scaffolds with similar microstructures and biomechanics to 
the native IVD tissues. It was determined that the fabricated scaffolds, in combination 
with IVD cells, may be suitable to promote IVD tissue regeneration as they encouraged 
cell morphology and arrangement similar to native IVD tissues.  In addition, the lamellar 
scaffold design and materials exhibited the necessary mechanical properties to match 
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CHAPTER 5 
5. FULLY CELLULARIZED 3-D TISSUE ENGINEERED CONSTRUCTS FOR 




 Currently an understudied aspect within the tissue engineering realm, research 
focusing on intervertebral disc (IVD) degeneration and treatments, has fallen short in 
their aims to improve patients’ quality of life.  The degenerated IVD, which causes 
intense low back pain, has been implicated in significant economic strain throughout the 
world.1   Clinical attempts to alleviate this pain, such as discectomy, spinal fusion, and 
disc replacements, are far from satisfactory as they focus only on the alleviation of some 
symptoms, while failing to address the underlying causes of disc degeneration.  To 
improve upon conventional clinical strategies, some researchers have begun to 
investigate unique approaches towards slowing IVD degeneration or promoting IVD 
tissue regeneration.  In the long term, the most ideal approach should involve the 
regeneration of IVD tissue.  Some current strategies focused towards regenerating IVD 
tissue have proven successful in promoting the synthesis of extracellular matrix (ECM) 
proteins similar to those present in the native tissue.2,3  However, current attempts 
towards regenerating IVD tissue do not accurately mimic the IVD histological 
microstructure, specifically the organized lamellar structure within the outer region of the 
IVD.   
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In order to successfully regenerate IVD tissue, there is a pressing need to fabricate 
tissue engineered scaffolds with a similar histological architecture of native IVD tissue.  
This is of vital importance, as it is widely known that cells respond to their physical 
environment.4  A scaffold with a controlled microstructure has the ability to guide and 
control cellular orientation and morphology.5  This is especially important for scaffolds 
aimed at regenerating the outer annulus fibrosus (AF) region of the IVD, as it is highly 
organized and possesses a concentric lamellar structure.6  Therefore, a scaffold which can 
mimic the native lamellar orientation of the native AF region would be able to control 
cellular alignment and morphology in accordance with the scaffold structure.  
Furthermore, studies have shown that ECM synthesis is controlled by cellular 
morphology.7,8  ECM composition as well as its structure, have been demonstrated to be 
affected by cell behavior on a tissue scaffold.  Therefore, a biomimetic IVD scaffold 
should control cellular structure and promote synthesis of ECM with similar orientation 
and composition.  This ultimately promotes the formation of a tissue structure with 
similar characteristics to that of native IVD tissue.    
To further expand upon the ability to mimic native ECM tissue histology, a 
strategy to create fully cellularized IVD scaffolds would prove to be favorable for tissue 
regeneration.  The ability to successfully retain seeded cells within a scaffold plays a 
critical role in encouraging the formation of a 3-D tissue.9  Cellularized structures are 
important due to the fact that they provide a necessary platform to promote the formation 
of functionalized, living tissue.  Currently, the attempts that have been made to create a 
cellularized IVD tissue structure have focused primarily on bioreactor systems, magnetic 
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seeding, or stacking of singular layered cell-biomaterial constructs.9-11  However, few 
other platforms have been investigated to encourage cellular infiltration within a tissue 
scaffold.  Therefore, a major task in promoting tissue regeneration is the ability to couple 
functional cells within biomaterial scaffolds.  A cellularized structure promotes the living 
functionality of the biomaterial scaffold for tissue regeneration.  Furthermore, it is likely 
that cellularized scaffolds will improve tissue formation, as cellularizing a tissue 
engineered scaffold in 3-D is required to form 3-D tissues.12,13   Many advances have 
been made in creating cellularized tissue scaffolds.14,15  Further, the ability of cells to be 
seeded within a scaffold is vital for the creation of 3-D tissue constructs.9  3-D 
cellularization better emulates the native tissue environment, promoting regenerated 
tissue and synthesized matrix more similar to native tissue.16,17  In this study, we describe 
a biofabrication strategy to aid in the rapid formation of a 3-D cellularized tissue 
engineered construct.  A home-made computer-controlled scaffold bioprinter were used 
to fabricate a 3-D scaffold fully mimicking the outer region of native IVD tissue. 
Multicellular chondrocyte spheroids were formed robotically using our home-made 
multicellular spheroid maker and then patterned robotically within the lamellar voids of 
the fabricated IVD scaffold structures.  Spheroids were used as they have previously 
shown to increase ECM content when compared to singular cells.19  This allowed the 
rapid cellularization of the scaffolding construct.  The 3-D multicellular spheroids began 
to attach and spread within the scaffold lamellae while exhibiting a similar cellular 
morphology as in the natural tissue.  Additionally, synthesized ECM composition and 
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structure within the 3-D cellularized IVD scaffold proved similar to that of the native 
tissue.    
To address the current issues faced with IVD tissue engineering, we have 
developed a unique biofabrication strategy to accurately mimic the histological hierarchy 
as well as the biomechanics of native IVD tissue.18  This technique offers the advantage 
of computer aided design (CAD), allowing precise control over the shape, as well as the 
defined microstructure, of the biomimetic IVD scaffolds.  Using this biofabrication 
strategy, it was shown that the lamellar IVD tissue histology could be simulated with the 
biomimetic scaffolds.  Further, this approach enables high resolution fabrication of 
reproducible scaffolding constructs using a variety of polymeric biomaterials.  To take 
advantage of the automated process, custom-made robotics were used to fabricate 3-D 
multicellular spheroids.  These multicellular spheroids were patterned into the void 
lamellar regions of the biomimetic IVD scaffold to create a functional cellularized tissue 
structure.  It was found that the 3-D cellularized scaffold emulated native IVD cellular 
structure as well as ECM matrix composition and structure.   Ultimately, a strategy 
similar to the one described here may be used to create a tissue engineered IVD structure 






5.2 Materials and Methods 
 
5.2.1 Scaffold Fabrication 
 
Scaffolds were fabricated using a home-made computer-controlled bioprinter.  
Medical grade polyurethane (PU) was dissolved in DMF at a concentration of 15%.  The 
solution was then extruded using a 3-D biofabrication device where the scaffold was 
designed using AutoCAD (Figure 5.1A).  Specifically, the polymer solution was extruded 
out through a micropipette-based needle (50 µm diameter) and onto a computer- and 
temperature-controlled collecting stage.  As the polymer solution was extruded through 
the tip, the solution viscosity drastically increased and it solidified instantly, as the 




Figure 5. 1: CAD design of the multilayered scaffold mimicking the overall shape and 
morphology of the native IVD tissue (A).  Software interface was developed to allow the 




5.2.2 Scaffold Characterization  
The dimensions and morphology of the printed scaffolds were analyzed using a 
JEOL LV-5610 scanning electron microscope (SEM) (JEOL Electronics Inc., Tokyo, 
Japan).  Specifically, the scaffolds lamellar layers and spacing were verified to match the 
lamellae size and spacing of native human IVD tissue.  Once this was confirmed, the size 
of the spacing between the lamellar layers was assessed. 
 
5.2.3 Multicellular Spheroid Fabrication 
In order to develop a truly 3-D, fully cellularized structure for IVD formation, we 
used multicellular spheroids as building blocks to seed into the scaffolds.  Using the data 
obtained from the SEM, it was determined that multicellular spheroids would need to be 
fabricated within a very specific size range in order to fit within the lamellae.  Bovine 
chondrocytes were used to create multicellular spheroids with uniform size using a home-
made spheroid maker.  The process can be seen in figure 5.2.  Briefly, a computer-
operated device was used to stamp molten 2% agarose PBS solution until the mold had 
hardened.  Cell suspensions were added into the agarose molds, and incubated at 37 °C 





Figure 5. 2:  (A) Plastic male-mold used to fabricate agarose microwells, (B-D) 
automated robotic stamping of agarose gel by the plastic male-mold, and thus (E) 
robotically produced agarose microwells. 
 
5.2.4 Scaffold Cellularization  
To seed the scaffolds, multicellular spheroids were pipetted into the prefabricated 
scaffolds using a custom-made computer-controlled robotic positioning system.  The 
chondrocyte spheroids were placed into the void lamellar scaffold spacing using precise 
positioning.  A schematic of this process can be seen in figure 5.3.  To compare the 
ability of spheroids to increase 3-D tissue formation, single cells were also seeded into 
the scaffolds as a control at the same cell number.  The scaffolds were cultured for 4 
weeks to create fully cellularized IVD scaffolding constructs.  Media was changed and 
collected throughout the culture period for further biochemical analysis of secreted ECM.  
An inverted microscope (Olympus Co., Tokyo, Japan) was used to monitor cell growth 
on the scaffolds.  
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Figure 5. 3: Schematic of spheroid deposition within IVD scaffold lamellae. 
 
5.2.5 Biochemical Analysis 
After 4 weeks in culture, the IVD tissue scaffolds were evaluated to determine the 
ECM content of the constructs.  Additionally, the molecules solubilized in the media 
supernatant were collected throughout the study to determine the amount of specific 
ECM released.  All colorometric assays were analyzed using a Synergy H1 Hybrid plate 
reader (Biotek, Winooski, VT, USA).  To determine the amount of ECM retained within 
the scaffolds, the samples were digested: in a papain solution 20  overnight at 60 °C for 
sulfated-glycosaminoglycan (sGAG) and hydroxyproline quantification, or in pepsin and 
elastase digest for 7 days at 4 °C for collagen I and II quantification.   In order to 
normalize the amount of newly formed ECM components, DNA content was quantified.  
The analyzed sGAG, hydroxyproline, and collagen types I & II quantities (µg) were 
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normalized by the average total DNA content (µg) to enable comparison between sample 
groups.  Additionally, the hydroxyproline content was normalized to sGAG to compare 
sample groups with values similar to native cartilage tissue.  The scaffolds seeded with 3-
D multicellular spheroids (experimental group) were compared to scaffolds seeded with 
single cells (control).    
 
5.2.5.1 DNA Quantification 
 In order to normalize the biochemical data between each test group, the DNA 
content within each scaffold group was analyzed using a DNA Quantitation Flourescent 
Assay Kit (Sigma-Aldrich, St.Louis, MO, USA).21  Briefly, 25 µL of cell digest solution 
in papain was combined with 200 µL of Hoeschst dye (2 µg/mL).  Standard curves were 
created using calf thymus DNA.  Fluorescence was read at 360 nm excitation and 460 nm 
emission. 
 
5.2.5.2 sGAG Synthesis 
Cellular production of sGAGs was analyzed using 1,9-Dimethyl-Methylene Blue 
(DMMB) salt (Sigma-Aldrich), similarly to techniques used by others.22  Briefly, 16 mg 
of DMMB was dissolved in 1 L of distilled water containing 3.04 g glycine, and 2.37 g 
NaCl and stirred overnight.  This was followed by the addition of 95 mL of 0.1 M HCl to 
give a pH of 3.0.  The solution was stored at room temperature and away from light.  50 
µL samples of cell digest solution in papain were then transferred into a flat bottom 96 
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well plate (Greiner Bio-One, Frickenhausen, Germany) containing 200 µL of DMMB 
reagent per well.  The absorbance was read at 525 nm.  Standard curves were created 
using chondroitin sulfate from shark cartilage (Sigma-Aldrich) with a linear 
concentration ranging from 0-100 µg/mL. 
 
5.2.5.3 Hydroxyproline Formation 
The total amount of collagen was analyzed using a hydroxyproline assay kit 
(Sigma-Aldrich), as hydroxyproline has been previously defined as a marker for overall 
collagen production.23,24  Briefly, 100 µL samples of cell digest solution in papain were 
hydrolyzed in the presence of 12 M HCl at 120 °C for 3 hours followed by evaporation of 
the samples.  Samples were reacted with Chloramine T for 5 minutes followed by an 
incubation with 4-(Dimethylamino)benzaldehyde (DMAB)for 90 minutes. Standard 
curves were created using the provided hydroxyproline standard. The absorbance was 
then read at 560 nm.   
 
5.2.5.4 Collagen Types I & II Synthesis  
After evaluating hydroxyproline content, additional biochemical analysis was 
needed to determine and quantify which types of collagen were present.  Specifically, 
collagen types I & II were chosen for an enzyme-linked immunosorbent assay (ELISA) 
analysis as they are the most prevalent collagens in the IVD.  Chondrex ELISAs for both 
collagen types I & II (Chondrex, Inc., Redmond, WA, USA) were used and the relevant 
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protocols were followed.  Briefly, capture antibodies were added to 96 well plates 
overnight, followed by a 2 hour incubation of the pepsin and elastase digested samples.  
Detection antibodies were then added for 2 hours followed by the addition of streptavidin 
peroxidase for 1 hour.  Then, the OPD chromagen was added for 30 minutes followed by 
the addition of 2N sulfuric acid to stop the reaction.  Collagen samples were compared 
against collagen standards and absorbance was read at 490 nm for both collagen types I 
& II.  
 
5.2.6 Immunohistochemistry 
Cellularized constructs were fluorescently analyzed to evaluate the presence and 
structure of collagen types I & II, and to visualize the cell nuclei.  Nuclei were stained 
with DAPI (blue), while collagens were stained using secondary antibodies (collagen 
type I: green, collagen type II: red).  Briefly, cellularized constructs were fixed in 4% 
paraformaldehyde and blocked using 4% goat serum.  Rabbit anti-bovine collagen type I 
polyclonal antibody (Millipore, Bedford, MA, USA) was added overnight followed by 
rinsing three times and the addition of Cy2-conjugated goat anti-rabbit IgG (Jackson 
ImmnoResearch, West Grove, PA, USA) and subsequent washing.  This was repeated for 
the mouse anti-collagen type II monoclonal primary antibody (Millipore) and the Cy3-
conjugated goat anti-mouse IgG (Jackson ImmnoResearch) followed by washing.  DAPI 
(Invitrogen, Carlsbad, CA, USA) was then used similarly to fluorescently label cell 
nuclei within the scaffold constructs.  Samples were observed using a Fluoview-FV1000 
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laser scanning confocal microscope (Olympus) to qualitatively analyze 3-D 
cellularization of the scaffolds and subsequent ECM formation. 
 
5.2.7 Statistical Analysis 
Data were expressed as mean ± standard error of mean.  An independent-sample 
t-test was performed on all biochemical analyses to compare the two IVD scaffold 
groups: 1) control scaffolds seeded with single cells, 2) experimental scaffolds seeded 
with multicellular spheroids. Significance was determined at p<0.05. SPSS V17 software 




5.3.1 Scaffold Structure 
 
 Utilizing our layer-by-layer and temperature controlled biofabrication strategy, 
reproducible multilayered 3-D scaffolds mimicking native IVD structures were easily 
fabricated.  The overall shape and structure of the native IVD was extensively studied in 
order to design biomimetic scaffolds with similar properties using AutoCAD.   A unique 
concentric lamellar structure was created, with each layer having a thickness of 50 µm 
and the spacing between each concentric lamellae at 175 µm.  This structure can be 
observed in the SEM image in figure 5.4, where the uniform and layered structure is 






Figure 5. 4: Overall image showing scaffold size and shape (A). SEM image showing 
multilayered scaffold structure with highly uniform and concentric lamellar layers 
mimicking native IVD structure (B). 
 
5.3.2 Spheroid Properties 
 
Using the robotic spheroid maker, highly uniform spheroids were fabricated with 
precise diameters of 125 µm using cell seeding densities of 1.3 x 104 cells/agarose mold 
(Figure 5.5).  This size proved optimal as it enabled the spheroids to be easily extruded 






Figure 5. 5:  Multicellular chondrocyte spheroids in culture within microwells, 
demonstrating a highly uniform diameter of 125 µm. 
5.3.3 Scaffold Cellularization  
 
After seeding, spheroids appeared to fully integrate within the scaffold lamellae.  
The multicellular spheroids began to fuse days after initial seeding.  After 1 week, the 
spheroids are fused and fully integrated with the scaffolds and formed 3-D tissues.   The 
single cells attached to the scaffolds and covered the entire structure, however, they failed 
to fully cellularize the lamellar voids as compared to the multicellular spheroids.  In the 
case of both the single cells and the multicellular spheroids, the cells within the lamellar 
voids oriented themselves in alignment with the lamellar scaffold structure.   
 
5.3.4 Biochemical Analysis 
 
The production of ECM by the tissue engineered constructs was identified by 
evaluating the amount of sGAG, hydroxyproline, and collagen types I & II in each 
sample after 4 weeks. A summary of the synthesized ECM composition retained within 
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the scaffolds can be seen in Table 1.  Additionally, a summary of ECM released within 
the media supernatant is given in Table 2.  The data is normalized to mean DNA content. 
 
Table 5. 1: Synthesized ECM within Scaffold after 4 weeks (Mean ± Standard Error of 
Mean). *p<0.05 
 GAG (µg) 
/ DNA (µg) 
Hydroxyproline 
(µg) / DNA (µg) 
GAG (µg) / 
Hydroxyproline (µg) 
Col I (µg) / 
DNA (µg) 
Col II (µg) 
/ DNA (µg) 
Spheroids 119.8 ± 
2.7* 
8.4 ± 1.1* 11.9 ± 1.4* 4.6 ± 0.9* 3.8 ± 0.1* 
Single Cells 54.4 ± 3.6 5.5 ± 0.4 8.3 ± 0.6 1.6 ± 0.2 1.8 ± 0.1 
 
 
Table 5. 2: Synthesized ECM Released in Supernatant after 4 weeks (Mean ± Standard 
Error of Mean). *p<0.05 
 GAG (µg) / DNA (µg) Col I (µg) / DNA (µg) Col II (µg) / DNA (µg) 
Spheroids 141.4 ± 11.1* 3.74 ± 1.0* 2.6 ± 0.3* 
Single Cells 108.9 ± 6.0 1.0 ± 0.3 1.1 ± 0.1 
 
5.3.4.1 sGAG Synthesis 
The amount of sGAG (spheroids 119.8 ± 2.7 µg/µg, versus single 54.4 ± 3.6 
µg/µg) retained within the construct was significantly greater in the scaffolds seeded with 
multicellular spheroids compared to the single cell controls, as shown in Figure 5.6A 
(n=7 per group, p<0.05).   Additionally, as shown in Figure 5.7A, the quantity of sGAG 
(spheroids 141.4 ± 11.1 µg/µg, versus single 108.9 ± 6.0 µg/µg) released into the 
supernatant was also significantly greater in the scaffolds seeded with multicellular 
spheroids compared to the single cell controls (n=7 per group, p<0.05).   
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5.3.4.2 Hydroxyproline Formation 
Hydroxyproline (spheroids 8.4 ± 1.1 µg/µg, versus single 5.5 ± 0.4 µg/µg) 
quantity was significantly greater in the scaffolds seeded with spheroids versus the single 
cells as seen in Figure 5.6B (n=7 per group, p<0.05). Additionally, the 
GAG/hydroxyproline ratio (spheroids 11.9 ± 1.4 µg/µg, versus single 8.3 ± 0.6 µg/µg) 
was also significantly greater in the scaffolds seeded with multicellular spheroids as seen 
in Table 1 (n = 7 per group, p<0.05). 
 
5.3.4.3 Collagen Types I & II Synthesis 
The amount of collagen type I (spheroids 4.6 ± 0.9 µg/µg, versus single 1.6 ± 0.2 
µg/µg) retained within the construct was significantly larger in the scaffolds seeded with 
spheroids versus the single cell control as seen in Figure 5.6C (n = 7 per group, p<0.05).  
Similarly, as shown in Figure 5.6D, the amount of collagen type II (spheroids 3.8 ± 0.1 
µg/µg, versus single 1.8 ± 0.1 µg/µg) preserved within the scaffold was significantly 
larger in the experimental group with multicellular spheroid seeded scaffolds (n = 7 per 
group, p<0.05).  Figure 5.7B shows that the quantity of collagen type I (spheroids 3.74 ± 
1.0 µg/µg, versus single 1.0 ± 0.3 µg/µg) released into the supernatant was significantly 
greater in the scaffolds seeded with spheroids versus the single cell control (n = 7 per 
group, p<0.05).  This was also observed for the amount of collagen type II (spheroids 2.6 
± 0.3 µg/µg, versus single 1.1 ± 0.1 µg/µg) released into the media was significantly 
larger in the experimental group with multicellular spheroid seeded scaffolds compared 































































































































































Figure 5. 6:  Results from biochemical analysis of ECM within the scaffolds 
cellularized with cell suspension and spheroids after 4 weeks.  Statistical analysis 
comparing groups showed significant differences for all study groups   (n =7 for each 
group, *p<0.05).   The sGAG (A), hydroxyproline (B), collagen type I (C), and collagen 
type II (D) content was all significantly greater in the scaffolds cellularized with 

























   
   





























































   
   


































Figure 5. 7:  Results from biochemical analysis of ECM released from scaffolds 
cellularized with cell suspension and spheroids over 4 weeks.  Statistical analysis 
comparing groups showed significant differences for all study groups   (n =7 for each 
group, *p<0.05).   The sGAG (A), collagen type I (B), and collagen type II (C) release 
was all significantly greater in the scaffolds cellularized with sperhoids than with the 





Image analysis provided qualitative evidence that the synthesized collagenous 
ECM was fully integrated within the voids of the lamellar structure in a similar fashion to 
native IVD tissue.  Further, cells as well as ECM, were organized in a 3-D configuration.    
The cell suspension (control) seeded into the biomimetic scaffolds synthesized some 
collagenous ECM, but cells only attached to the scaffold surface and failed to synthesize 
enough ECM to fill in the lamellar void (Figure 5.8A-D).  A side projection view 
showing that the seeded cells in suspension attached to the scaffold surface and secreted 
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extracellular molecules, but failed to secrete biomolecules occupying the lamellar void 
space as the matrix only accumulated on the scaffold surface as shown in figure 5.8E-H.  
On the other hand, the multicellular spheroids fully infiltrated the scaffold lamellae and 
grew in a 3-D fashion that enabled the creation of a completely cellularized IVD 
construct.  Further, staining of collagenous ECM within the lamellae appeared to be 
much greater in the scaffolds seeded with spheroids versus single cells, as synthesized 
matrix can be seen throughout the entire lamellar voids (Figure 5.8I-L).   A side 
projection view proving that the multicellular spheroids fully cellularized the lamellar 











Figure 5. 8: Fluorescent images showing chondrocyte growth and ECM synthesis in 
the scaffolds.  An overview of the cell suspension controls seeded onto the scaffold 
after 4 weeks can be seen in: (A) nuclei, (B) collagen type II, (C) collagen type I, and 
(D) merged image.  A side projection view of the single cells on the scaffold shows that 
the cells were superficially adhered to the scaffold surface and did not cellularize the 
lamellar region while only producing ECM along the scaffold surface: (E) nuclei, (F) 
collagen type II, (G) collagen type I, and (H) merged image. 
In comparison, an overview of the spheroids seeded onto the scaffold shows that the 
entire construct is cellularized with large quantities of ECM produced : (I) nuclei, (J) 
collagen type II, (K) collagen type I, and (L) merged image.   A side projection view of 
the spheroids within the scaffold further validates that the spheroids have cellularized 
the lamellar void and have produced ECM in a 3-D manner: (M) nuclei, (N) collagen 
type II, (O) collagen type I, and (P) merged image.  The dotted zone in (H) and (P) 










           The field of tissue engineering aims to regenerate living tissue that possesses a 
similar structure and function to the natural healthy tissue, with the ultimate goal of 
replacing the targeted diseased tissue.  Tissue engineering often utilizes scaffolds as a 
template to guide cell growth and tissue formation.  The structure of tissue engineered 
scaffolds is important as it not only dictates the mechanical integrity of the construct, but 
also guides cell behavior and function as well as new ECM organization.  For these 
reasons, it is important for the scaffold structure to closely mimic the native tissue 
architecture in order to successfully regenerate the native tissue.  The corresponding 
structure will control cell behavior, and ultimately cellular function.  Due to current 
limitations in achieving a cell-based functional scaffold that simulates the native tissue, 
an approach was developed to provide a fully cellularized-construct for IVD tissue 
regeneration. 
 First, biomimetic IVD scaffolds were fabricated using a novel biofabrication 
approach that allowed for the creation of a scaffold with an overall morphology and 
microstructure which strongly resembles the architecture of the native IVD tissue. 
Advantages of our scaffold over other methods currently being investigated is the use of 
an organized lamellar structure, which is more similar to native collagen fibril structure 
present in the IVD.25   Our fabricated scaffold had the ability to mimic the structure, layer 
thickness, and interlamellar spacing of the native human IVD, as similar values have 
been reported in the literature for these characteristics.26-28  As discussed above, by 
closely mimicking this structure we believe we will be able to more effectively 
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regenerate a tissue construct that is highly similar to native IVD tissue, which has been 
identified as a major challenge in tissue engineering the IVD.29  Further, the interlamellar 
spacing provided by our scaffolds will allow for cell infiltration and ECM organization. 
 The novel biofabrication approach discussed above, along with a robotic seeding 
strategy, allowed for the ability to organize cell density and distribution within the tissue 
scaffold, directly controlling the capacity to form 3-D tissue engineered constructs.  
Typically, after seeding cells onto a 3-D scaffold, it is difficult for cells to further fill up 
the whole volume of the scaffold and the cells end up adhering only to the scaffold 
surface.20,30  This results in a tissue engineered scaffold that is not entirely or 
homogenously cellularized due to the decreased cell content within the void regions.  
Furthermore, the majority of studies involving cell-biomaterial constructs use single cells 
or cell suspensions where cells are only able to adhere to the surface of the scaffold 
material and pore walls.  Therefore, these seeding techniques are not able to actually 
cellularize the whole pores or voids themselves within the constructs.  A major issue with 
the use of single cells in these applications is a low cell retention within the constructs.31  
To circumvent these issues, 3-D multicellular spheroids were fabricated to have a slightly 
smaller diameter than the lamellar voids of the fabricated IVD scaffolds.  The 
chondrocyte spheroids were then deposited into the lamellar voids where they attached to 
the scaffold lamellae and aligned along the structures in a 3-D fashion similar as in the 
native tissue.  Single cells were seeded onto the IVD scaffold as controls.  It was found 
that this unique strategy of incorporating spheroids within the scaffold provides an 
efficient and quick 3-D cellularization of the construct, which has been described as a 
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major challenge.9  Further, after initial seeding, cell spheroids began to fuse together 
followed by cellular adhesion to the scaffold.  Eventually, the spheroids formed a 3-D 
cell layer which was entirely homogenous, avoiding challenges met by others attempting 
to cellularize 3-D scaffolds.32  Furthermore, the spheroids synthesized ECM throughout 
the scaffold voids, comparable to the matrix formed within the natural IVD, while the cell 
seeded by suspension only produced matrix on the scaffold surface.   
Multicellular spheroids showed excellent ingrowth within the lamellar voids of 
the IVD scaffolds, which led to a more uniform distribution of cells within the 3-D 
structure.  Further, it appears that these spheroids encouraged organized tissue formation, 
with the production of ECM such as collagens and GAGs, within the lamellar spacing of 
the scaffold. As expected, larger values for retained ECM components were obtained 
with the cellular spheroids as they aided in the preservation of more ECM components.  
This is similar to what others have observed.33,34  Specifically, the values we observed for 
GAG content within the spheroid cellularized scaffold are within values reported by 
others for native cartilage tissues and also tissue engineered constructs.33,35-40  
Additionally, our data regarding the GAG/Hydroxyproline ratio correlates well with other 
studies involving cartilage and IVD tissue, with values between 2:1 and 27:1.41  Based on 
the observed hydroxyproline levels, indicative of overall collagen content, and further 
biochemical analysis of specific collagen types, it is evident that collagen types I & II are 
the major constituents of the collagenous ECM within the IVD constructs.  Further, the 
collagen content within our structures is also similar to what others have reported for 
tissue engineered constructs.42   Our results showed similar amounts of collagen types I & 
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II, though, there were larger overall quantities of collagen type I as compared to collagen 
type II.  This ratio is similar to that seen in the AF region of the IVD tissue, which this 
scaffold aims to replace.43  
We believe that the reason the scaffolding constructs seeded with spheroids 
retained more matrix is because they provided a 3-D platform for cell growth while 
promoting the synthesis and entrapment of matrix more similar to that of native tissue.  
As seen in the results, there was not only a significant increase in the amount of ECM 
production within the scaffolds cellularized with spheroids, but also a significant increase 
in the amount of ECM released into the supernatant.  We believe that the scaffolds seeded 
with spheroids produced and released more ECM due to the 3-D cell morphology of the 
spheroids within the scaffold lamellae, which better mimics the native tissue atmosphere.  
The 3-D cellular and matrix interactions provided by the spheroids more closely emulates 
the native tissue environment.44 However, the increase in matrix production in the 
spheroid cellularized scaffolds may be due to the fact that a more hypoxic environment 
was created, as nutrient diffusion to the cells within the spheroids may be decreased.  
Many studies have shown an increase in ECM synthesis (GAGs and collagens) when 
chondrocytes are placed in a hypoxic environment, more similar to that of native IVD 
tissue.45-49  
Upon further examination of the 3-D tissue engineered constructs, 
immunostaining showed uniform cell distributions throughout the entire thickness of the 
spheroid cellularized scaffolds when compared with the single cell scaffolds.  
Subsequently, ECM deposition was also found throughout the scaffold thickness in the 
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spheroid seeded scaffolds. Collagen type I staining appeared to mimic the scaffold, 
especially in the scaffold cellularized with spheroids, perhaps proving that the ECM was 
indeed mimicking the scaffold structure.  Further, collagen type II showed up throughout 
the voids within the lamellar scaffold.  These results show that multicellular spheroids 
better integrate within the IVD scaffold than cells from suspension and synthesize 




This study is the first of its kind attempting to fabricate a fully cellularized 3-D 
tissue construct for IVD tissue regeneration.  The purpose of this study was to create a 
unique IVD scaffold which provided the ability to create a homogenous cell distribution 
throughout the structure. This improved upon current cell seeding methods by creating a 
fully cellularized scaffold environment with similar matrix compositions to that of native 
IVD tissue.  The techniques described in this paper are not limited to an IVD scaffold, 
and have the ability to be applied to various tissue scaffold technologies.  It is our hope 
that in the future this approach could be used, in certain applications, to replace 
conventional 2-D culture methods by providing a more native 3-D physiological 
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The major impact of this work is in the development of a new technology useful in the 
biofabrication of tissue engineering scaffolds, especially for the fabrication of scaffolds 
for IVD tissue regeneration.  This technology is based upon a custom-made additive 
manufacturing platform which enables the precise deposition of polymeric biomaterials 
to form structures with similar microstructures and mechanical properties to the targeted 
native tissue.  Preliminary studies revealed the potential of the fabricated scaffold 
structures to improve upon current IVD scaffold fabrication technologies.  Detailed 
conclusions are summarized below, by chapter. 
 
Chapter 3: A novel technology was developed which utilized unique additive 
manufacturing techniques.  This technology allowed for the extrusion of polymeric 
solutions into 3-D scaffold structures that more closely mimicked the morphology and 
structure of native IVD tissue.  This was accomplished by extruding a polymeric solution 
through micropipettes onto a temperature-controlled collecting platform.  By precisely 
controlling the temperature of the solution, the device enables the precise control of the 
polymeric deposition and allows the solution to be directly solidified due to the drastic 
decrease in temperature and subsequent increase in polymer solution viscosity.   
Evidence was provided for the ability of this biofabrication platform to utilize various 
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polymer solutions.  Biocompatible and biodegradable polyurethane (PU) was used for 
this study.  It was determined that the fabricated IVD scaffolds had a unique shape and 
microstructure, which was highly similar to the native tissue structure, and unlike any 
tissue scaffold developed to date.  Further, scaffolds demonstrated favorable 
biocompatibility and mechanical properties, indicating that they could serve as an 
excellent approach for use in IVD tissue regeneration applications. 
 
Chapter 4:  Within this chapter, an extension of the previous study is presented.  It was 
demonstrated that the custom-developed biofabrication strategy could be used with 
multiple polymeric solutions to broaden its impact on the ability to create clinically 
relevant scaffolds for IVD tissue regeneration.  Specifically, an ultraviolet (UV) curable 
chitosan-gelatin (Chs/Gtn) material developed in our lab was extruded using the same 
fabrication method previously described.  The scaffolds’ overall shape and microstructure 
proved to mimic the native IVD tissue and histological ECM structure.  Further, it was 
shown that the IVD scaffolds’ lamellar size and spacing could be accurately controlled to 
fabricate biomimetic IVD scaffolds.  Cellular behavior, specifically cell alignment in 
accordance with the scaffold, was analyzed and compared to native tissue.  Results 
indicated that the scaffolds had the capability to control cellular morphology similar to 
that of native tissue.  Additionally, the mechanical properties of the scaffold were 
evaluated.  It was demonstrated that the scaffolds’ elasticity as well as dynamic stability 
were highly similar to that of native IVD tissue.  
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Chapter 5:  In this experiment, the biofabricated IVD scaffold structures were 
extensively evaluated in vitro.  To further validate the advances in our scaffold 
fabrication process, the ability to create 3-D cellularized IVD scaffolds was thoroughly 
investigated.  The unique aspects of biofabrication were fully utilized within this study, 
as 3-D multicellular spheroids were first created using a novel robotic approach, followed 
by their positioning within the biofabricated scaffolds’ lamellae.  The spheroids provided 
a 3-D platform for the cells to adhere and grow within the scaffold material.  Further, the 
newly formed ECM was analyzed and proven to exhibit a highly similar structure and 
composition to native IVD tissue.  This study shows the potential of biofabrication to 
provide unique solutions towards the creation of a 3-D cellularized structure for tissue 
regeneration. 
 
6.2 Limitations & Challenges 
Biomimetic IVD scaffolds for tissue regeneration were successfully created using novel 
biofabrication technologies presented in this dissertation.   These scaffolds demonstrated 
very promising in vitro results.  However, several challenges had to be overcome, with 
some still remaining, before having the ability to develop a more functional and clinically 
relevant engineered IVD scaffold for tissue regeneration.  Some of these challenges are 
discussed and arranged by chapter below. 
 
Chapter 3:  A biofabrication method was presented revealing the ability to successfully 
create lamellar scaffolds for IVD tissue regeneration.  The major challenge that had to be 
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overcome when fabricating the scaffolds was troubleshooting and optimizing the 
fabrication parameters of the custom-made device.  We needed to investigate motor 
speeds, polymer solution viscosity, polymer extrusion rate, freezing temperature, and 
micropipette extrusion diameter.  Once these parameters were determined, issues 
involving ambient humidity and solvent evaporation still arose as the scaffold fabrication 
process depends on precisely controlled conditions.  During mechanical testing of the 
fabricated structures, it was determined that the mechanical properties of the PU scaffolds 
were far from ideal.  Even though the elastic modulus was within the lower values 
reported for the human IVD, it is our belief that the scaffolds may need to be altered to 
improve their mechanical strength. 
 
Chapter 4:  Different polymeric solutions were utilized in this study to prove the ability 
of the biofabrication method to take advantage of the beneficial properties of various 
biomaterials.  However, in order to ensure the effectiveness of using the new biomaterial 
solutions, the biofabrication parameters had to be optimized once again.  Although the 
mechanical properties were significantly improved using the Chs/Gtn material compared 
to the PU used in chapter 3, there is still room for improvement of the mechanical 
stability of the structure in order to create a clinically relevant IVD tissue replacement. 
 
Chapter 5:  3-D multicellular spheroids were used as building block to form a fully 
cellularized tissue structure. While the spheroids were easily positioned into the voids of 
the lamellar spacing and providing a feasible 3-D platform for 3-D tissue formation, the 
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cells were not able to migrate into the lamellar scaffold material due to the low porosity. 
We plan to advance the fabrication process by incorporating a porogen during the 
scaffold fabrication process so that cells can penetrate into the whole scaffold. 
 
6.3 Future Goals 
The ultimate goal of this project was to develop a unique biofabrication based 
technology for use in the creation of advanced functional scaffolds for IVD tissue 
regeneration.  The immediate goals will be to address the challenges listed above while 
expanding upon the technologies developed here to improve the scaffolds.  In the larger 
scheme, this biofabrication technology can be elaborated upon to fabricate better IVD 
scaffolds as well as other types of scaffold structures for various types of tissue in the 
body.  Future plans and goals are summarized below. 
One future objective is to advance the biofabrication platform to improve cellular 
response.  The aim is to aid in the adhesion of the multicellular spheroids to each other, 
which may be accomplished by coating the spheroids in ECM protein or ECM-derived 
peptides, such as fibronectin, prior to extrusion within the scaffold lamellae.  This would 
aid in cell fusion and create an entirely cellularized structure.   
As for improving the tissue regeneration response to the biofabricated IVD 
strategy, we plan to control the differentiation of mesenchymal stem cells (MSCs) into 
IVD cell phenotypes by incorporating signaling molecules into and within the scaffold 
using nano-layer-by-layer (nanoLBL) technology as well as nanoparticle-based delivery.  
These techniques can be used to create a spatial and temporal release profile from the 
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IVD scaffold.  Therefore, MSC differentiation can be regionally controlled using 
different combinations of biomolecules to produce specific cell lineages within the IVD. 
We have already discovered candidate signaling molecules to encourage stem cell 
migration and proliferation within the scaffold. In vitro studies analyzing the release 
kinetics of these molecules will then be performed.  This will enable optimized 
differentiation cocktails to be created for each IVD region which support gene expression 
similar to native IVD tissue.  The current challenges discussed above are being addressed 
to improve the biofabrication strategy. 
Finally, the ultimate goal of this project is to assess in vivo growth of IVD tissue 
by using these signaling molecules in combination with the biomimetic IVD scaffold to 
recruit endogenous stem cells and control their proliferation and IVD phenotypic 
differentiation.  With the proper combination of signaling molecules, the scaffolds will 
recruit endogenous stem cells and encourage proliferation, chondrogenic differentiation, 
and synthesis of ECM similar to that of native IVD tissue. Scaffolds will first be created 
with immobilized signaling molecules, followed by implantation and histological 
evaluation in subcutaneous rodent models.  We also aim to assess the regenerated tissue 
by evaluating the mechanical properties and comparing those values to native IVD tissue.  
  
 
 
